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1  Introduction 
1.1 Atherosclerosis 
In 2016, Cardiovascular diseases (CVD) were the cause of death of approximately 17.9 
million people, representing 31% of all deaths worldwide (status 2017, World Health 
Organization). Atherosclerosis plays a decisive role in this regard. Atherosclerotic 
alterations can lead to stroke, coronary heart disease (CHD) or peripheral artery disease 
(PAD). As a growing number of people are exposed to multiple cardiovascular risk 
factors, such as obesity, arterial hypertension, hypercholesterolemia, diabetes, nicotine 
or alcohol abuse, the incidence of CVD is increased. The probability of developing 
cardiovascular disease also increases with age and the average life expectancy 
constantly rises. For these reasons, it is important to understand the exact molecular 
mechanisms and the interaction of the different cell types involved in atherosclerotic 
development and progression, in order to find new preventive or drug-based methods 
for treatment. 
1.1.1 Development and Progression 
Atherosclerosis is a disease concerning alterations in human arteries. Arterial vessels 
consist of three different layers. The tunica intima is the innermost layer, followed by the 
tunica media and the tunica adventitia as the external layer (reviewed in Tegos et al., 
2001). The tunica intima consists of the endothelium, facing the vessel lumen with the 
circulating blood and the internal lamina elastica consisting of elastin, forming the 
outermost part. In between endothelium and lamina elastica, the so-called 
subendothelial space is composed of extracellular matrix molecules produced by a few 
resident smooth muscle cells (SMC) and also contains resident macrophages (MФ) and 
pluripotent cells are present (reviewed in Bobryshev et al., 2016; Libby et al., 2011). 
Beneath the tunica intima lies the tunica media consisting of SMC, producing elastin, 
elastic and collagenous fibres. Thereafter, the external elastic lamina, composed of 
elastin is followed by the adventitia as the outer layer of the vessel. This layer of 
connective tissue consists of elastic and collagenous fibres with embedded small 
diameter blood and lymphatic vessels for nutrient supply, whereas the tunica intima and 
tunica media are nourished by diffusion of molecules from the blood in the arterial lumen 
(reviewed in Tegos et al., 2001).  
Already in the 19th century, Rudolf Virchow described the pathology of atherosclerosis 
as inflammation (reviewed in Gisterå & Hansson, 2017). In 1913, Nikolai Antischow used 
rabbits to demonstrate the correlation between cholesterol feeding and atherosclerosis 
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development (reviewed in Gisterå & Hansson, 2017). More than 60 years later, Ross et 
al. (1977) published their „response-to-injury“-hypothesis, postulating that 
atherosclerotic lesion arises from „injury“ of the endothelium as the initiating event (Ross 
et al., 1977). This was a generally accepted postulation, since certain areas of arteries 
were found to be especially prone to atherosclerotic lesion development. This includes 
arterial branching points and bends, where the local disturbance in the blood flow is 
thought to cause endothelial dysfunction, leading to the invasion of circulating molecules 
into the subendothelial space (reviewed in Bobryshev et al., 2016). In 1995 Williams and 
Tabas postulated the alternative „response-to-retention“-hypothesis. Searching for a key 
event, which is absolutely required as the stimulus to induce atherosclerotic changes, 
they found that the endothelial injury is not a common feature, since atherogenesis can 
be initiated without endothelial denudation (Williams & Tabas, 1995). They refined the 
„response-to-injury“-hypothesis, stating that changes in the endothelium increases its 
permeability, leading to lipoprotein retention within the arterial wall as the common key 
event in atherogenesis (Williams & Tabas, 1995). Today, atherosclerosis is in general 
described as a chronic inflammatory disease triggered by the retention of lipoproteins in 
the arterial wall (reviewed in Bobryshev et al., 2016). There are several risk factors 
known to promote increased endothelial permeability such as smoking, hypertension, 
diabetes mellitus and dyslipidemia (reviewed in Libby et al., 2019). 
Based on the present knowledge, the initiating event in atherosclerosis progression is 
the infiltration of circulating low-density lipoprotein (LDL) particles into the subendothelial 
space. The retention of these particles on proteoglycans leads to their trapping and 
biochemical modification through proteases and lipases, which promotes aggregation 
and further increases proteoglycan binding (reviewed in Gisterå & Hansson, 2017). One 
prominent LDL modification is the oxidation by myeloperoxidase, lipoxygenase and 
reactive oxygen species (ROS) found in the subendothelial space (reviewed in Gisterå 
& Hansson, 2017), but also by resident MФ located in the arterial wall (reviewed in Glass 
& Witztum, 2001). The generated oxidized LDL (oxLDL) is internalized by endothelial 
cells (EC) through the lectin-like oxidized LDL receptor-1 (LOX-1) (reviewed in Pirillo et 
al., 2013). This initiates an intracellular signaling cascade in the EC, resulting in the 
expression of E-selectin, P-selectin, vascular cell adhesion molecule-1 (VCAM-1) and 
intracellular adhesion molecule-1 (ICAM-1) as well as the production of monocyte 
chemoattractant protein-1 (MCP-1) (reviewed in Pirillo et al., 2013). This leads to the 
recruiting, rolling, adhesion and finally migration of monocytes and leukocytes into the 
subendothelial space (reviewed in Bobryshev et al., 2016). Furthermore, oxLDL inhibits 
the production of nitric oxide (NO) in EC and inactivates NO by increasing cellular ROS 
production (reviewed in Pirillo et al., 2013). NO is a chemical mediator with anti-
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atherogenic properties including vasorelaxation, inhibition of leukocyte-endothelial cell 
adhesion, platelet adhesion and SMC proliferation (reviewed in Pirillo et al., 2013). In the 
subendothelial space, the transmigrated monocytes proliferate and differentiate into MΦ 
in response to oxLDL (Frostegard et al., 1990) or in response to MФ colony stimulating 
factor (MCSF) expressed by EC (reviewed in Gisterå & Hansson, 2017). Thereafter, the 
activated MΦ are polarized to a pro-inflammatory phenotype, called M1 MФ (reviewed in 
Bobryshev et al., 2016). These M1 MΦ increasingly express scavenger receptors like 
SR-A1, cluster of differentiation 36 (CD36) or LOX-1, which account for 75 – 90% of the 
oxLDL internalization (reviewed in Moore et al., 2013). Unlike LDL-receptors, scavenger 
receptors are not downregulated in response to intracellular lipid accumulation, a 
protective mechanism to avoid foam cell formation (reviewed in Gisterå & Hansson, 
2017). The uncontrolled uptake of oxLDL promotes an pro-inflammatory response 
induced by the assembly of toll-like receptors (TLRs) regulated by CD36 (reviewed in 
Park, 2014; Yu et al., 2013). Activated MΦ secrete pro-inflammatory cytokines such as 
tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6), which 
together with ROS further promote the inflammatory response as well as monocyte and 
T-lymphocyte recruitment (reviewed in Pirillo et al., 2013). Furthermore, the loss of MΦ-
polarity is induced by oxLDL, inhibiting the ability to re-migrate into the blood stream 
(reviewed in Pirillo et al., 2013). This traps them in the subendothelial space, leading to 
the failure of inflammation resolution and promoting lesion progression (reviewed in 
Pirillo et al., 2013). Even though there is a large number of pro-inflammatory MΦ in 
atherosclerotic lesions, alternatively activated anti-inflammatory M2 MΦ are also 
detected in the more stable regions of the plaque (reviewed in Bobryshev et al., 2016). 
These type of MΦ are more resistant to foam cell formation and secrete anti-
inflammatory factors such as interleukin-10 (IL-10) and interleukin-1 (IL-1) (reviewed in 
Bobryshev et al., 2016). The M1 phenotype is primarily found in progressing plaques, 
whereas the M2 phenotype is present in regressing plaques, where M2 MΦ are involved 
in tissue repair and remodelling (reviewed in Bobryshev et al., 2016). Therefore, the 
presence of the different phenotypes may reflect the plaque progression and stability 
(M1 subtype) or regression (M2 subtype) (reviewed in Bobryshev et al., 2016). During 
plaque progression, the unregulated uptake of oxLDL in MΦ renders them into foam 
cells, which increasingly produce ROS (reviewed in Pirillo et al., 2013). The oxLDL-
derived cholesterol-accumulation in foam cells ultimately leads to the initiation of the 
apoptotic pathway by the protein p53 (Kinscherf et al., 1998). The released lipids and 
cell debris accumulate extracellular in the plaque (reviewed in Libby et al., 2011). The 
ineffective clearance of these residues by MΦ, called efferocytosis, further promotes the 
formation of a lipid-rich pool (reviewed Libby et al., 2011). This so-called necrotic core, 
consists of apoptotic and necrotic cells, cholesterol crystals and other extracellular 
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material (reviewed in Gisterå & Hansson, 2017). Not only dying MΦ, also apoptotic SMC 
and EC contribute to the necrotic core (reviewed in Pirillo et al., 2013). Upon oxLDL 
trapping, SMC from the media are stimulated to migrate into the subendothelial space 
(reviewed in Maiolino et al., 2013). The proliferation of these SMC is induced by oxLDL 
(reviewed in Pirillo et al., 2013), ROS and the platelet-derived growth factor (PDGF), 
secreted by MΦ and EC (reviewed in Maiolino et al., 2013).  
SMC are able to take up oxLDL by LOX-1 receptors, inducing their proliferation and 
transdifferentiation into MΦ-like cells (reviewed in Gisterå & Hansson, 2017). 
Approximately 30% of the plaque SMC express MΦ-markers due to lipid-loading 
(reviewed in Gisterå & Hansson, 2017). The remaining plaque SMC produce an 
extracellular matrix composed of collagen, which forms a fibrous cap above the necrotic 
core and contributes to its stabilization (reviewed in Gisterå & Hansson, 2017). Thereby, 
enhanced cell migration and proliferation, as well as the formation of the necrotic core is 
shown in clinical manifestations such as flow-limiting stenosis, which leads to tissue 
ischemia or provoke thrombus, interrupting blood flow locally or embolizing arteries 
(reviewed in Libby et al., 2011). Generally, there are different stages during 
atherosclerotic progression. Early lesions, called fatty streaks, are identified by 
cholesterol-engorges MФ in the subendothelial space. These fatty streaks are already 
found in the first decade of life, but they are not clinically significant, since they are 
reversible and asymptomatic (reviewed in Lusis, 2000). Fibrous lesions or fibrous 
plaques are characterized by a growing necrotic core consisting of mostly cholesterol 
esters and other cell debris from apoptotic or necrotic cells with an overlaying fibrous cap 
made of extracellular matrix from SMC (reviewed in Lusis, 2000). In advanced plaques, 
this fibrous cap is degraded by MMP, which are secreted by MΦ, EC and SMC (Galis et 
al., 1994; reviewed in Pirillo et al., 2013). This alters the lesion to a vulnerable plaque 
and decreases its ability to withstand the pulsatile forces from the blood, rendering it 
prone to rupture (reviewed in Gisterå & Hansson, 2017). Vulnerable plaques are 
characterized by a thin, collagen-poor fibrous cap with only a few SMC and abundant 
inflammatory cells (reviewed in Lusis, 2000). Rupture of a vulnerable plaque, commonly 
occurs at the lesion edges, so called plaque shoulders (reviewed in Lusis, 2000). This 
rupture exposes the necrotic core content to coagulation proteins in the blood, triggering 
thrombosis (reviewed in Libby et al., 2011).  
The aforementioned processes are illustrated in Figure 1, showing the initial trapping 
and modification of LDL in the subendothelial space with the subsequent activation of 
EC, MΦ and SMC and following processes.  
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Figure 1: Atherosclerosis development and progression. Various risk factors can lead to endothelial 
dysfunction and allow lipoproteins to enter the subendothelial space, where they get trapped on 
proteoglycans and can be modified. The resulting expression of adhesion molecules on the ECs and the 
secretion of chemokines enable the adhesion and migration of monocytes and T-lymphocytes. Monocytes 
differentiate into MΦ upon oxLDL-exposure and cytokines, secreted by ECs. MФ take up the oxLDL via their 
scavenger receptors and stimulate the migration and proliferation of SMCs from the media. SMCs secrete 
various extracellular matrix components and thus, contribute to the formation of a fibrous cap above the 
necrotic core consisting of dead foam cells. This fibrous cap may get weakened by its degradation through 
MMPs, secreted by MΦ, SMC and EC (Maiolino et al., 2013; modified). 
1.1.2 Lipid metabolism in MФ  
In the literature, cholesterol and oxLDL are regularly mentioned, when referring to 
atherosclerosis and foam cell formation. Cholesterol is a sterol, which is an important 
plasma membrane component, ensuring membrane fluidity as well as lipid raft assembly 
and function (reviewed in McLaren et al., 2011). Also, it serves as a precursor for steroid 
hormones (reviewed in McLaren et al., 2011). Cholesterol can be produced de novo in 
the liver or is supplied by food intake. Since cholesterol is a hydrophobic molecule, it is 
transported in the bloodstream via lipoproteins. These particles can accommodate 
cholesteryl esters, triglycerides and other lipids in their hydrophobic core and are 
surrounded by a hydrophilic monolayer consisting of apolipoproteins and phospholipids 
(reviewed in McLaren et al., 2011; Moore & Tabas, 2011). The different lipoproteins are 
characterised according to their density and thus, their centrifugation behaviour, 
distinguishing chylomicrons, very low-density lipoprotein (VLDL), intermediate-density 
lipoprotein (IDL), low-density lipoprotein (LDL) and high-density lipoprotein (HDL) 
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(reviewed in Moore & Tabas, 2011). These different lipoproteins have different transport 
pathways within the body and possess different apolipoproteins, as they are the crucial 
recognition and docking molecule for the membrane receptors of the different target cells 
(reviewed in McLaren et al., 2011). 
As mentioned before, one key initiating step in atherogenesis is the retention and 
oxidation of LDL in the subendothelial space, triggering the complex immune response 
described in the previous chapter. For clearance of this oxLDL from the intima, MΦ are 
the main cell type removing the subendothelially localized oxLDL by phagocytosis. 
Therefore, recruited monocytes undergo morphological and structural changes, while 
differentiating into MΦ. The intensification of metabolism, enhanced expression of 
surface receptors, altered sensitivity to signalling molecules and an increased lysosomal 
enzyme activity are induced in order to prepare the cells for active phagocytosis and 
digestion of engulfed material (reviewed Bobryshev et al., 2016). MΦ phagocytize oxLDL 
via the scavenger receptors like CD36, SR-A1 or LOX-1 (reviewed in Chistiakov et al., 
2016). Thereafter, oxLDL is hydrolysed in lysosomes by the lysosomal acid lipase (LAL) 
(reviewed in Chistiakov et al., 2016). The emerging free cholesterol (FC) and free fatty 
acids (FFA) may be used for cellular needs, e.g. in cell membranes (reviewed in 
Fernandez-Ruiz et al., 2016). Esterification of free cholesterol, that is not immediately 
required, occurs at the endoplasmic reticulum (ER) and is catalysed by acetyl-CoA 
acetyltransferase-1 (ACAT-1). Thereafter, the lipid droplets (LDs) originate from the ER, 
composed of a hydrophobic lipid core containing triglycerides and cholesteryl esters (CE) 
to a varying extend (reviewed in Ouimet, 2013). When needed, these esterified lipids can 
be re-hydrolysed in the cytosol by neutral cholesteryl ester hydrolase-1 (nCEH-1) 
(reviewed in Chistiakov et al., 2016). Alternatively, lipolysis occurs by cargo-specific 
autophagy, in this case lipophagy, in the autophagolysosome by LAL (reviewed in 
Ouimet, 2013). In the case of excess lipid accumulation, FC is bound to HDL as acceptor, 
which transports the cholesterol to the liver for excretion (reviewed in Jeong et al., 2017). 
This reverse-cholesterol transport (RCT) is crucial for cell homeostasis, as most cells 
cannot catabolize excess cholesterol (reviewed in Remmerie & Scott, 2018). In MΦ the 
RCT depends on the lipoprotein HDL, as acceptor for FC as well as two members of the 
ABC transporter subfamily A and G, namely ABCA-1 and ABCG-1 (reviewed in 
Remmerie & Scott, 2018). These transporters are membrane proteins that are able to 
actively transport different substances across the cell membrane to various acceptors, 
by consuming adenosine-triphosphate (ATP) (reviewed in Vasiliou et al., 2009). When 
HDL is not available as acceptor, FC is re-esterified by ACAT-1 at the ER for further 
storage (reviewed in Ouimet, 2013). Furthermore, under physiological conditions CE in 
MΦ undergoes constitutive cycles of esterification and hydrolysis as a measure to control 
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cholesterol availability for cell membranes (reviewed in Ouimet, 2013). The re-
esterification of FC by ACAT-1 functions as a protective response to excess FC 
accumulation, when the RCT-pathway is saturated (reviewed in Jeong et al., 2017). One 
rate-limiting step in the efflux of FC is the hydrolysis of neutral lipids from the LDs, since 
only FC, not CE can be exported to HDL (Ouimet, 2013). A special role in lipolysis and 
RCT was attributed to autophagy, since autophagosomes can deliver LDs for bulk 
degradation to the lysosome for hydrolysis, followed by ABC transporter-dependent 
efflux (reviewed in Jeong et al., 2017; Singh & Cuervo, 2012). This autophagy-dependent 
lipolysis for RCT is called lipophagy and was found to be activated in MΦ during excess 
lipid loading conditions, like in atherosclerotic plaque (Ouimet et al., 2011). The 
aforementioned phagocytosis, intracellular processing and RCT of oxLDL in MΦ is 
depicted in Figure 2.  
 
Figure 2: MФ cholesterol metabolism. Cholesteryl esters are transported in the blood system bound to 
lipoproteins like LDL. In the subendothelial space, LDL is oxidized and binds with high affinity to scavenger 
receptors (SR-A1, CD36, LOX-1) expressed on MΦ. After phagocytosis, oxLDL is hydrolysed in the 
lysosome by LAL, generating FC. Thereafter, FC is used for cellular needs or can be exported out of the 
cell. Furthermore, MΦ can store lipids within lipid droplets (LDs) for later usage. Therefore, FC is esterified 
by ACAT-1 at the ER. For reverse cholesterol transport (RCT) out of the cell, CE, which is stored in LDs, is 
re-hydrolysed 1. by neutral CE hydrolase-1 (nCEH-1) in the cytosol, or 2. LDs in whole or in part can be 
degraded by autophagy, involving lysosomal hydrolyzation. Both ways are common under normal 
conditions, whereas the latter is especially important during excess lipid loading conditions. The anew 
emerging FC can be exported by the transporters ABCA-1 or ABCG-1 to extracellular acceptor HDL. When 
no acceptor is available or the transporters capacity is reached, FC is re-esterified for further storage.  
The balance between hydrolysis and esterification to maintain cholesterol homeostasis, 
preventing foam cell formation is extremely sensitive and fragile (reviewed in Chistiakov 
et al., 2017). MΦ have different accommodation mechanisms during increased lipid 
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burden. The accumulation of cellular cholesterol activates different transcription factors 
in order to elevate ABCA-1 and ABCG-1 expression for increased RCT (reviewed in 
Remmerie & Scott, 2018). Additionally, the increased LAL activity upon elevated lipid 
influx also contributes to the regulation of ABCA-1 activity and expression (reviewed in 
Jeong et al., 2017). Nevertheless, in advanced lesions the dominating pro-inflammatory 
stimuli upregulate the expression of scavenger receptors, downregulate the ABCA-1 and 
ABCG-1 transporters, increase ACAT-1 activity and downregulate nCEH-1 activity, 
leading to a dysregulated MΦ lipid-handling, ultimately initiating apoptosis and necrotic 
core formation (reviewed in Chistiakov et al., 2017). Furthermore, for the efficient 
efferocytosis of apoptotic cells by surrounding MΦ, an intact lipid metabolism is required 
(reviewed in Moore et al., 2013). A dysfunctional lipid metabolism further increases 
apoptotic events in the atherosclerotic plaque and decreases efferocytosis, resulting in 
secondary necrosis, further contributing to the necrotic core expansion (reviewed in 
Moore et al., 2013). This seems to be a fatal cycle, since an increased plaque lipid burden 
not only contributes to the plaque volume, but also enhances the plaque associated 
inflammation (reviewed in Ghosh et al., 2010). With prolonged lipid burden, the protective 
mechanisms for lipid handling are overwhelmed, leading to the accumulation of FC in 
various cell- and organelle membranes (e.g. lysosomes and ER) (reviewed in Moore et 
al., 2013). This impairs their activity, ultimately inducing apoptosis by further triggering 
inflammation and stress responses (reviewed in Moore et al., 2013). Since lesional MΦ 
mainly accumulate CE-enriched lipid droplets (reviewed in Ouimet, 2013) and 
unmodified LDL was not found to cause CE-accumulations as massively as modified 
LDL in plaque MΦ (reviewed in Chistiakov et al., 2017), oxLDL still remains the primarily 
lipid causing foam cell formation in atherosclerosis. 
As already mentioned, one protective mechanism during excess lipid loading is MΦ 
lipophagy (Figure 2). This pathway degrades LDs in bulk to avoid foam cell formation 
(reviewed in Ouimet et al., 2011). Besides MΦ lipophagy, autophagy was described to 
be activated in numerous cell types involved in atherosclerotic lesions (reviewed in De 
Meyer & Martinet, 2009). In the following chapter the autophagy process and autophagy 
in atherosclerosis are described in further detail. 
1.2 Autophagy 
Autophagy is an evolutionary conserved intracellular lysosomal pathway for degradation 
and recycling of various cellular constituents including excess or damaged organelles, 
misfolded or aggregate-prone proteins and infectious agents (reviewed in Bento et al., 
2016; Cecconi & Levine, 2008). Generally, there are three forms of autophagy, 
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distinguished on basis of mechanism of cargo sequestration (reviewed in Hansen et al., 
2018). Microautophagy describes the sequestration of cytoplasmic components directly 
into the lysosomes for acid hydrolase degradation (reviewed in Hansen et al., 2018). 
Chaperone-mediated autophagy is the selective degradation of proteins with the 
KFERQ-like motif, which are recognized by chaperones, then unfolded and translocated 
to the lysosome (reviewed in Hansen et al., 2018). Finally, macroautophagy refers to the 
degradation of cytosolic material via the sequestration into double-membrane vesicles, 
called autophagosomes, which fuse with lysosomes for cargo degradation (reviewed in 
Hansen et al., 2018). The fusion of the outer autophagosomal membrane with the 
lysosomal membrane, give rise to the autophagolysosome, where the formal inner 
autophagosomal membrane with its content is degraded by lysosomal hydrolases 
(reviewed in Christian et al., 2013). This described macroautophagy is hereafter referred 
to as autophagy.  
Autophagy is a constitutive process, being active in most mammalian cells at basal 
levels, functioning as a homeostatic mechanism (reviewed in Christian et al., 2013). It 
gets increasingly activated during starvation and related cellular stress, degrading 
macromolecules to provide energy (reviewed in Bento et al., 2016). Nevertheless, it is 
also involved in cellular development, differentiation and aging (reviewed in Christian et 
al., 2013). Autophagy plays an important role in health and disease, since it can degrade  
aggregate-prone intracytoplasmic proteins causing various neurodegenerative disorders 
like Dementia, Parkinson- or Huntington-Disease (reviewed in Bento et al., 2016). 
Furthermore autophagy appears to have roles in metabolic and cardiac disease, stroke 
and hematopoiesis (reviewed in Bento et al., 2016). In the innate and adaptive immunity, 
autophagy acts protectively against infectious disease caused by pathogenic agents 
(reviewed in Bento et al., 2016; Christian et al., 2013).  
1.2.1 Autophagic process 
Autophagosomes are formed throughout the cytoplasm and are trafficked along 
microtubules via dynein to bring the double-membrane vesicles in proximity to lysosomes 
(reviewed in Bento et al., 2016). The autophagosomes originate from precursor 
structures, called the phagophore, which start growing from both ends sequestering bulk 
cytoplasm and organelles until it finally closes (reviewed in Cecconi & Levine, 2008). The 
first identification of autophagy-relevant genes (ATG) essential for autophagosomes 
formation was mostly carried out in yeast and later on the mammalian orthologs were 
identified (reviewed in Bento et al., 2016). The autophagic process can be distinguished 
in autophagy initiation, membrane nucleation, cargo recognition, membrane elongation 
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and closure, followed by autophagosome maturation through the fusion with the 
lysosome to form the autophagolysosome and finally the degradation (reviewed in 
Christian et al., 2013). The key upstream regulators in autophagy include the nutrient 
sensors mammalian target of rapamycin (mTOR) and adenosine monophosphate-
activated kinase (AMPK) (reviewed in Hansen et al., 2018). The mTOR complex 1 
(mTORC1) is a cell-growth regulator, integrating nutrient signals and cytokines from 
different pathways, acting as inhibitor for autophagy and promoting cell growth (reviewed 
in Li et al., 2016). Whereas AMPK is a conserved heterotrimeric protein kinase, acting 
as key energy sensor, maintaining the balance of ATP generation and consumption, 
thereby affecting cell growth and proliferation (reviewed in Zhu et al., 2017). Under 
normal physiological conditions, mTORC1 acts as kinase and inactivates the Unc-51-
like kinase 1 (ULK1) complex, a conserved kinase, which serves as the key upstream 
initiator of autophagy (reviewed in Hansen et al., 2018). When nutrients are lacking, 
adenosine monophosphate increases, leading to the AMPK-mediated activation of the 
ULK1 complex for autophagy induction (reviewed in Cecconi & Levine, 2008). 
Simultaneously, AMPK represses the mTORC1 kinase activity (Kim, et al., 2011). ULK1 
is a tetrameric kinase complex formed by ULK1, ATG13, ATG101 and FAK-family 
interacting protein of 200 kDa, FIP200 (reviewed in Bento et al., 2016). After activation, 
ULK1 phosphorylates activating molecule in Beclin-1-regulated autophagy (AMBRA) 
which activates the phosphatidylinositol 3-kinase (PI3K) III nucleation complex, 
composed of vacuolar protein sorting 15, VSP15, VPS34, ATG14 and Beclin-1 (reviewed 
in Li et al., 2016). Thereafter, the PI3K III complex marks a distinct ER membrane with 
phosphatidylinositol 3-phosphate (PI3P). This recruits two ubiquitin-like conjugation 
systems to the phagophore initiation site, essential for phagophore elongation and 
closure (reviewed in Chun & Kim, 2018). One is the ATG12 conjugation system, including 
ATG12, ATG5 and ATG16L1 (reviewed in Chun & Kim, 2018). Initially, this complex-
formation is triggered by ATG7 in an ATP-dependent way, transferring ATG12 to the E2-
like conjugating enzyme ATG10, forming the ATG12-ATG10 intermediate (reviewed in 
Li et al., 2016). Next, ATG12 is covalently attached to ATG5 and finally the interaction 
with the homodimer ATG16L1 creates the ATG12-ATG5-ATG16L1 conjugate, called the 
ATG12 conjugation system (reviewed in Li et al., 2016). This conjugate operates as a 
E3 ubiquitin ligase, playing a role in the phagophore membrane nucleation, elongation 
and closure (reviewed in Chun & Kim, 2018). Furthermore, the ATG12 conjugation 
system is involved in the procession and translocation of the microtubule associated 
protein light chain 3 (LC3) to the phagophore membrane (reviewed in Chun & Kim, 2018). 
LC3 is firstly cleaved by the cysteine protease ATG4 into LC3 I and further processed by 
ATG7 and ATG3 (reviewed in Chun & Kim, 2018). Finally, LC3 I is conjugated to the 
substrate phosphatidylethanolamine (PE), now called LC3 II, with the help of the ATG12 
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conjugation system and attached to the autophagosomal membrane (reviewed in Chun 
& Kim, 2018). Even if the phagophore originates from the ER membrane, the 
autophagosomal membrane is not entirely composed of ER-membrane fragments. 
Mitochondria, the trans-Golgi network, late endosomes and the plasma membrane also 
contribute to the phagophore elongation by providing parts of their membranes, 
orchestrated with the help of ATG9 (reviewed in Chun & Kim, 2018). LC3 II also 
participates in cargo recognition by interacting with various autophagy receptors or cargo 
receptors bound to proteins or organelles (reviewed in Hansen et al., 2018). One of these 
autophagy receptors is the protein sequestosome-1/p62, which recognizes ubiquitylated 
proteins and organelles targeted for degradation (reviewed in Hansen et al., 2018). 
These autophagy receptors are mandatory for selective autophagy and clearance of 
specifically marked cargo (reviewed in Hansen et al., 2018). After the LC3 II-orchestrated 
sequestration of p62 and its cargo into the autophagosome, the autophagosomal 
membrane closes. After closure, the ATG12 conjugation system dissolves from the outer 
autophagosomal membrane, being available for further autophagosome build-up 
(reviewed in Mehrpour et al., 2010). Since LC3 II is localized in both, the inner and outer 
autophagosomal membrane, it dissociates from the outer membrane, but remains on the 
inner membrane after autophagosome closure and is later on degraded in the 
autolysosome (reviewed in Chun & Kim, 2018).  The newly formed autophagosome with 
its sequestrated cargo is now transported to lysosome, where the outer autophagosomal 
membrane fuses with the lysosomal membrane to form the autophagolysosome, 
regulated by the cytoskeleton and lysosomal membrane proteins like lysosomal 
associated membrane proteins-1 and -2 (Lamp-1 and Lamp-2) (reviewed in Li et al., 
2016). This releases the now single-membrane autophagic vesicle into the lysosomal 
lumen with its acid enzymes and degrades the autophagic body including its cargo 
(reviewed in Dikic & Elazar, 2018). The emerging catabolic products are released in the 
cytoplasm for recycling or for export (reviewed in Li et al., 2016). These different stages 
in the autophagy process and the mentioned key regulators are depicted in Figure 3.  
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Figure 3: Autophagy signaling pathway. Upon cellular stress, autophagy is initiated by the activation of 
AMPK and by repressing the inhibitory effect of mTORC1 on the ULK 1 initiation complex. This leads to 
changes in the kinase activity of ULK1, recruiting AMBRA1 to activate the PI3K III nucleation complex. These 
complexes then translocate to the ER membrane, initiating membrane remodeling to give rise to the 
phagophore. Besides the ER membrane, other membrane contributors are the plasma membrane, the Golgi-
network, mitochondria and endosome. Essential for the phagophore elongation and closure, as well as the 
cargo sequestration into the growing autophagosome, are the two ubiquitin-like conjugation systems 
composed of ATG12-ATG5-ATG16L1 and LC3 II. After autophagosome closure, ATG12-ATG5-ATG16L1 
dissociate from the autophagosomal membrane, being available for further autophagosome formation. The 
LC3 II on the inner membrane remains with the sequestered, ubiquitinated cargo and its autophagy adaptor 
p62. After fusion of the outer autophagosomal membrane with the lysosome, the remaining autophagic 
vesicle is degraded by lysosomal enzymes. The emerging components can be re-used for cellular needs or 
exported out of the cell.  
1.2.2 Autophagy in Atherosclerosis 
While the autophagic process is constantly occurring at basal level in the cell, autophagy 
is more apparent in a wide range of diseases, including CVD (reviewed in Martinet & De 
Meyer, 2009). In numerous cell types, found in human atherosclerotic plaques, 
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autophagy activity was verified by transmission electron microscopy and 
immunohistochemical analysis (Liu et al., 2015). SMC and MΦ in the fibrous cap, as well 
as ECs of the plaque shoulders, increasingly expressed LC3 II as evidence for increased 
autophagic activity (Liu et al., 2015). An increased autophagic activity in atherosclerosis 
seems to be reasonable, since several autophagic triggers like inflammatory mediators, 
ROS and oxLDL are present in atherosclerotic plaques (reviewed in Maiuri et al., 2013). 
During lesion formation autophagy is thought to protect plaque cells against oxidative 
stress, inflammation, hypoxia and metabolic stress, promoting cell survival, decelerating 
plaque progression and promoting plaque stability (reviewed in De Meyer & Martinet, 
2009; Maiuri et al., 2013). Though, excessively stimulated autophagy may cause cell 
death of SMC, leading to reduced collagen synthesis and plaque destabilization 
(reviewed in De Meyer & Martinet, 2009). Whereas autophagy-induced apoptosis of ECs 
can lead to acute clinical events by promoting lesional thrombosis (reviewed in De Meyer 
& Martinet, 2009).  
In plaques of atherogenic mice, MФ predominantly expressed autophagy-related 
proteins like ATG8, LC3 or p62 (Liao et al., 2012; Razani et al., 2012; Liu et al., 2016). 
In atherosclerotic plaques of ApoE-/- mice on western diet for <2 months, plaques in the 
aortic root showed high levels of LC3 expression and much of this LC3 was co-localized 
with p62 (Sergin, et al., 2017), indicating an intact autophagy. After 3-4 months on 
western diet, these mice still had high levels of p62, but the LC3 expression was reduced 
and the LC3 / p62 co-localization markedly vanished, indicating a declined 
autophagosome formation (Sergin, et al., 2017). Human atherosclerotic plaques, 
obtained from discarded carotid endarterectomy specimens were dissected, 
distinguishing regions with no, minimal or maximal atherosclerotic changes (Sergin et 
al., 2017). Areas lacking atherosclerotic changes only expressed LC3 and no p62, 
indicative for basal autophagy without accumulation of autophagic cargo (Sergin et al., 
2017). In minimally diseased regions and advanced lesions p62 was detectable, whereas 
LC3 intensity was found to be reduced and p62 co-localized with polyubiquitin, indicative 
for marked cargo by autophagic degradation (Sergin et al., 2017). Furthermore, in 
advanced atherosclerotic plaques, increased p62 accumulations were found together 
with bigger lesion sizes and larger necrotic cores (Liao et al., 2012; Razani et al., 2012). 
Analyses on MΦ-specific ATG5-deficiency in atherogenic mice, compared with MΦ-
specific ATG5-potent mice showed an increased plaque formation and inflammasome 
hyperactivation, indicated by elevated IL-1ß serum levels as well as aortic IL-1ß 
expression (Razani et al., 2012). Furthermore, in atherosclerotic mice models, MΦ 
autophagy-deficiency caused increased apoptosis and oxidative stress, ultimately 
promoting plaque necrosis and impairing lesional efferocytosis (Liao et al., 2012). As 
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already described, MΦ autophagy is an important mechanism to resolve the 
subendothelial accumulated oxLDL by aiding in MΦ lipid homeostasis (Ouimet et al., 
2011). This protects from foam cell formation and furthermore ensures the efficient 
efferocytosis of death cells by MΦ (reviewed in Kurdi et al., 2016). However, the initial 
protective autophagy is impaired with lesion progression, since with increasing plaque 
burden p62- and ubiquitin-tagged protein inclusions increase, indicative for a 
compromised autophagic clearance (reviewed in Evans et al., 2017). A dysfunctional 
autophagy was shown to enhanced plaque formation by influencing multiple atherogenic 
aspects like foam cell, inflammasome hyperactivation, enhanced apoptosis with 
concomitant defects in efferocytosis and finally accumulation of cytotoxic organelles and 
proteins (reviewed in Sergin & Razani, 2014). Due to these anti-atherogenic properties 
and to rescue autophagy activity in atherosclerotic plaque, multiple groups experimented 
with rapamycin or rapamycin-derivates (e.g. Everolimus) to activate autophagy by mTOR 
inhibition. Inducing autophagy by mTORC1 inhibition indeed showed to attenuate 
atherosclerotic plaque progression (Baetta et al., 2009; Beutner et al., 2012; De Meyer 
et al., 2012; Martinet et al., 2007; Mueller et al., 2008; Verheye et al., 2007). Although 
this is a promising new therapeutic approach, there are still a lot of investigations 
required to establish this method of treatment. 
1.3 Growth-Differentiation-Factor-15  
1.3.1 The cytokine GDF-15 
Growth-differentiation-factor-15 (GDF-15) was firstly described in a sequence analysis 
of activated MΦ by Walsh et al., 1995. Due to a seven cysteine domain in the protein 
sequence, GDF-15 was classified as cytokine divergently belonging to the transforming 
growth factor-β superfamily (TGF-β) (Fairlie et al., 1999). GDF-15 is synthesized as a 62 
kDa dimeric propeptide and after cleavage by a furin-like protease, its secreted as a 25 
kDa disulfide-linked dimeric protein (Fairlie et al., 1999). Various adult tissues e.g. brain, 
prostate, kidney, lung, liver and spleen, heart, thymus and pituitary gland express GDF-
15 (Böttner, Suter-Crazzolara, et al., 1999; Böttner, Laaff, et al., 1999). In addition, GDF-
15 expression is increased in human placenta (Lawton et al., 1997) and the developing 
brain (Schober et al., 2001). The cytokine GDF-15 is a useful marker for diagnostic and 
risk stratification, since it is expressed and secreted upon multiple stress factors (e.g. 
inflammation, oxidative stress, hypoxia, telomere erosion and oncogene activation) 
(reviewed in Brown et al., 2006; Wollert et al., 2016). Increased GDF-15 levels are 
associated with obesity, cancer, diabetes or CVD such as hypertrophy, heart failure, 
endothelial dysfunction and atherosclerosis (reviewed in Adela & Banerjee, 2015). 
Therefore, GDF-15 was attributed a role in metabolic, cardiovascular and chronic 
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diseases, as well as obesity and cancer, making it an useful biomarker (reviewed in 
Adela & Banerjee, 2015). Several studies investigated the relation between GDF-15 
serum levels and various diseases. Healthy women with higher baseline GDF-15 serum 
levels were found to be at increased risk for cardiovascular events (Brown et al., 2002; 
Lin et al., 2014). In elderly individuals, GDF-15 was found to be a strong predictor of all-
cause and non-cardiovascular mortality (Daniels et al., 2011). The cytokine GDF-15 is 
also described to influence metabolic processes (reviewed in Emmerson et al., 2018). In 
this context, GDF-15-deficient mice revealed an increased body weight and had 
increased adipose tissue due to increased food intake (Tsai et al., 2013). Furthermore, 
GDF-15-deficient mice were more prone to high-fat-diet (HFD)-induced obesity (Tran et 
al., 2018) and prone to increased lipid-deposition in the liver (Kim et al., 2018). Mice with 
diet-induced obesity, treated with GDF-15, showed weight loss due to lower food intake 
(Mullican et al., 2017; Tsai et al., 2018). Transgenic mice overexpressing GDF-15 had 
decreased body weight and less white adipose tissue (Kim et al., 2013; Macia et al., 
2012), improved glucose tolerance, lower insulin levels and were reported to be resistant 
to dietary- and genetic-induced obesity (Chrysovergis et al., 2014; Macia et al., 2012). 
1.3.2 GDF-15 in atherosclerosis 
Several studies reported an elevated GDF-15 serum level as a strong predictor for 
cardiovascular events (reviewed in Adela & Banerjee, 2015). The expression of GDF-15 
in mononuclear cells and MΦ is induced by various stimuli like IL-1β, IL-2, TNF-α, MCSF, 
Phorbol-12-myristate-13-acetate (PMA), ceramide, oxLDL or hydrogen peroxide, thus 
GDF-15 is associated with MΦ activation (Bootcov et al., 1997; Fairlie et al., 1999; 
Schlittenhardt et al., 2004; Schober et al., 2001). Furthermore, GDF-15 is increasingly 
expressed in the atherosclerotic artery wall, where it colocalizes with plaque MΦ 
(Bonaterra et al., 2012; de Jager et al., 2011). GDF-15 was found to influence MΦ lipid 
homeostasis (Wu et al., 2014), additionally, MΦ showed increased GDF-15 expression 
upon oxLDL-exposure. In vitro analyses revealed an impact of GDF-15 on the cholesterol 
efflux by increased expression of the ABCA-1 transporter, also known as the cholesterol 
efflux regulatory protein [CERP] (Wu et al., 2014). Furthermore, an elevated circulating 
level of GDF-15 is associated with endothelial activation and vascular inflammation 
(Eggers et al., 2012). A pro-atherogenic impact of GDF-15 has been reported by 
Bonaterra et al. (2012) and de Jager et al. (2011). The expression of the pro-
inflammatory cytokine IL-6 was significantly decreased in peritoneal MΦ from GDF-15-/- 
/ ApoE-/- mice compared to MΦ from ApoE-/- mice, when exposed to 100 µg/ml oxLDL for 
12h (Bonaterra et al., 2012). Furthermore, peritoneal MΦ from GDF-15-/- / ApoE-/- mice 
incubated with 20 ng/ml rGDF-15 for 12h showed elevated IL-6 expression (Bonaterra 
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et al., 2012). GDF-15 mRNA and protein levels increased in peritoneal MΦ of ApoE-/- 
mice after 12 and 20 weeks on a cholesterol-enriched-diet (CED) (Bonaterra et al., 
2012). Additionally, GDF-15-deficient mice, which had been fed a CED displayed an 
increased body weight, as well as blood triglyceride- and cholesterol levels (Bonaterra 
et al., 2012). Though, CED-fed GDF-15-/- / ApoE-/- mice revealed decreased lumen 
stenosis in the aortic arch compared to CED-fed ApoE-/- mice (Bonaterra et al., 2012). In 
agreement with this, de Jager et al. (2011) reported an upregulation of GDF-15 in murine 
atherosclerotic lesions with disease progression. They used LDLR-/- mice transplanted 
with bone marrow from GDF-15-/- mice, which received a western-diet for 4 to 12 weeks 
(de Jager et al., 2011). These double-knockout mice showed reduced MΦ infiltration, 
decreased necrotic core formation as well as improved plaque stability (de Jager et al., 
2011). However, anti-atherogenic effects of GDF-15 were published by Johnen et al. 
(2012) and Preusch et al. (2013). LDLR-/- mice transplanted with bone marrow from GDF-
15-/- mice with 24 weeks atherogenic-diet showed an increase of lesional-MΦ 
accumulation and thinner fibrous caps compared to control mice (Preusch et al., 2013). 
Johnen et al. (2012) investigated a model for advanced atherosclerosis, by keeping 
ApoE-/- mice, which also overexpressed GDF-15, on a high-fat-diet for 6 months. ApoE-
/- mice overexpressing GDF-15 revealed smaller lesions in the aortic sinus and thoracic 
aorta, but showed no differences in lesion composition compared to ApoE-/- mice. 
Likewise, neither changes in the cytokine production nor in serum levels of lipids were 
detectable, comparing ApoE-/- mice overexpressing GDF-15 to ApoE-/- mice (Johnen et 
al., 2012). These studies attribute GDF-15 as an important, yet ambiguous role in 
atherosclerosis, especially in plaque MΦ. Though, the varieties concerning the used 
atherosclerotic mouse-models and the variability in the duration of atherogenic-diet 
should be considered, when comparing these findings.  
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1.4  Aim of this study 
Autophagy was found being highly activated and acting protective in human 
atherosclerotic lesions (Liao et al., 2012; Razani et al., 2012). Especially in MΦ, 
autophagy is involved in RCT to prevent foam cell formation (Ouimet et al., 2011), lesion 
progression and necrotic core formation (Liao et al., 2012; Razani et al., 2012). The 
cytokine GDF-15 was also found to be implicated in MΦ lipid efflux (Wu et al., 2014) and 
is highly expressed in plaque MΦ (Schlittenhardt et al., 2004). Therefore, in this study 
the impact of the cytokine GDF-15 on MΦ autophagy and lipid homeostasis was 
investigated. By influencing MΦ autophagy, GDF-15 could be a valuable target in 
atherosclerosis by reducing plaque size or improving plaque stability through regulation 
of autophagy activity. In order to investigate the impact of GDF-15 on MΦ autophagy and 
lipid homeostasis, we examined the autophagy and lysosome activity, as well as the lipid 
loading and cholesterol levels using THP-1 MΦ with modified GDF-15 protein level. 
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2 Material and Methods 
2.1 Material 
2.1.1 Instruments/Equipment 
Table 2: Instruments/Equipment with producer in alphabetical order. 
Instrument/Equipment Producer 
Autoklav Heratherm Oven OMS 100 Fisher Scientific GmbH, Schwerte, 
Germany 
Bench HERASafe® HS18 Kendro Laboratory Products GmbH, 
Hanau, Germany 
Bioanalyzer 2100 Agilent Technologies Inc., Santa Clara, 
USA 
Camera AxioCam MRm  Carl Zeiss AG, Oberkochen, Germany 
Centrifuge Perfect Spin P PEQLAB Biotechnologie GmbH, 
Erlangen, Germany 
Centrifuge Pico 17 Heraeus Holding GmbH, Hanau, 
Germany 
Centrifuge Heraeus ™ Biofuge PrimoR Thermo Fisher Scientific Inc.  
Waltham, USA 
Chip Priming Station Agilent Technologies Inc., Santa Clara, 
USA 
Confocal laser scanning microscope 
Nikon Eclipse Ti 
Nikon GmbH, Geschäftsbereich 
Mikroskope, Düsseldorf, Germany 
Cytation™ 3 microplate reader BioTek Instruments Inc., Winooski, VT, 
USA 
FIREBOY plus safety Bunsen Burner INTEGRA Biosciences GmbH, 
Fernwald, Germany 
Fusion-SL 3500.WL Imaging System PEQLAB Biotechnologie GmbH, 
Erlangen, Germany 
Heracell™ 150 Co2 Incubator Thermo Fisher Scientific Inc.  
Waltham, USA 
Hybridization Oven MK II MWG-Biotech AG, Ebersberg, Germany 
HydroFlex™ Microplate Washer Tecan Group Ltd; Männedorf, 
Switzerland 
Ice-crasher Scotsman AF103 Kälte Kamrath GmbH & Co.KG, Linden, 
Germany 
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Kern KB 3600-2N Precision balance  
0.01gr : 3600gr 
Kern & Sohn GmbH, Balingen, Germany 
Magnetic stirrer IKA® C-MAG MS4 IKA®-Werke GmbH & Co. KG, Staufen, 
Germany 
Mini Trans-Blot® Cell  Bio-Rad Laboratories Inc., Hercules, 
USA 
MJ-Research PTC-200 Thermocycler Global Medical Instrumentation Inc., 
Ramsey, USA 
Multipipette® plus Eppendorf AG, Hamburg, Germany 
Mx3005P qPCR System  Agilent Technologies Inc., Santa Clara, 
USA 
NanoDrop 200C, UV-Vis 
Spectrophotometer 
Thermo Fisher Scientific Inc., Waltham, 
USA 
Nikon Eclipse TS 100 Invert Microscope Nikon GmbH, Düsseldorf, Germany 
pH-Meter 761 Calimatic. Knick Elektronische Messgeräte GmbH 
& Co.KG, Berlin, Germany 
Pipetman Classic™ P10, P20, P100, 
P200, P1000 
Gilson Inc. Middleton, USA 
Pipetus® 100-240 Volt Hirschmann Laborgeräte GmbH & Co. 
KG, Eberstadt, Germany 
Platform shaker Promax 1020 Heidolph Instruments GmbH & Co.KG, 
Schwabach, Germany 
PowerEase® 500 Power Supply Life Technologies GmbH, Darmstadt, 
Germany 
Tecan Sunrise Microplate Reader Tecan Group Ltd; Männedorf, 
Switzerland 
Microtube Thermoshaker PHMT-PSC-18 Grant Instruments Ltd., Cambridge, UK 
TKA GenPure with xCAD Dispenser Thermo Electron LED GmbH, 
Niederelbert, Germany 
Ultrasonic bath Sonorex BANDELIN Electronic GmbH & Co.KG, 
Berlin, Germany 
PCR Workstation Pro PEQLAB Biotechnologie GmbH, 
Erlangen, Germany 
Vakuum concentrator Bachhofer: BA-VC-
300H  
Mc Labor oHG, Albstadt, Germany 
Vakuum pump BVC 21 NT VACUUBRAND GmbH & Co. KG, 
Wertheim, Germany 
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Vortexer MS 3 IKA®-Werke GmbH & Co. KG, Staufen, 
Germany 
Vortexer VTX-3000L Uzusio LMS Consult GmbH & Co. KG, 
Brigachtal, Germany 
Zeiss Axiovert 135  
(inverted epifluorescence microscop) 
Carl Zeiss AG, Oberkochen, Germany 
XCell SureLock™ Mini Cell 
Electrophoresis System 
Life Technologies GmbH, Darmstadt, 
Germany 
2.1.2 Consumption items 
Table 3: List of consumption items with producer in alphabetical order. 
Consumption item Producer 
12-well, 24-well, 96-well CELLSTAR® 
Multiwell culture plates 
Greiner Bio-One International GmbH, 
Kremsmünster, Austria 
96-well Immuno Plates, transparent, 
U96 MaxiSorp (GDF-15 Elisa) 
Fisher Scientific GmbH, Schwerte, 
Germany 
96-well Polysterol Microplate, 
transparent 
(BCA-Protein-Assay) 
Greiner Bio-One International GmbH, 
Kremsmünster, Austria 
AriaMx 96-well skirted low profile plate 
(RT-PCR) 
Agilent Technologies Inc., Santa Clara, 
USA 
Amersham Protran® Premium 0,2µM 
NC 
Nitrocellulose Blotting Membran 
GE Healtcare Life Science, Freiburg, 
Germany 
C-Chip DHC-N01 Neubauer improved Digital Bio, Hopkinton, USA 
Cell flasks T25, T75, T175 Stand., 
Vent.Cap. 
Sarstedt AG & Co, Nümbrecht, Germany 
Cell Scraper 300mm TPP techno Plastic Products AG, 
Trasadingen, Switzerland 
Combitips advanced 0.5 ml, 5 ml Eppendorf AG, Hamburg, Germany 
Lumox® multiwell, 96-well plate Sarstedt AG &Co., Nümbrecht, Germany 
Microcentrifuge Tube w/lid, 0,5 ml BrandTech Scientific Inc., Essex, UK 
Nitrile gloves Nobaglove-Nitril NOBA Verbandmittel Danz GmbH & Co. 
KG, Wetter, Germany 
NuPAGE™ Novex™ 4-12% Bis-Tris 
Protein Gels, 1.0 mm, 12-well  
Life Technologies GmbH, Darmstadt, 
Germany 
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Optical strip caps (12 strips) 
(RT-PCR) 
Agilent Technologies Inc., Santa Clara, 
USA 
PARAFILM® "M" Pechiney Plastic packing, Chicago Il., 
USA 
SafeSeal Tips Premium Cell Saver, 0.1-
1000 µl, steril 
Biozym Scientific GmbH, Hessisch 
Oldendorf 
SafeSeal Microtubes, 0.5 ml,1.5 ml, 2 
ml, transparent 
Sarstedt AG & Co., Nümbrecht, Germany 
Serological Pipette, with cottonplug, 
5 ml, 10 ml, 25 ml 
SARSTEDT AG & Co., Nümbrecht, 
Germany 
Slide-A-Lyzer Dialysis Cassettes 7K 
MWCO (nLDL oxidation) 
Thermo Fisher Scientific Inc., Waltham, 
USA 
Tube, 15 ml and 50 ml SARSTEDT AG & Co., Nümbrecht, 
Germany 
TTP cell scraper 240mm TPP Techno Plastic products AG, 
Trasadingen, Switzerland 
Whatman ® Blotting Paper GE Healthcare Life Science, Freiburg, 
Germany 
2.1.3 Reagents and Substances 
Table 4: Reagents and substances with producer in alphabetical order. 
Reagents/Substances Producer 
Acetic acid 100% Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Agarose standard Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
AllStars Negative Control siRNA QIAGEN GmbH, Hilden, Germany 
AllStars Hs Cell Death siRNA QIAGEN GmbH, Hilden, Germany 
Bovine Serum Albumin (BSA) 
Fraktion V  
PAA Laboratories GmbH, Pasching, Austria 
Calciumchlorid-Dihydrate Merck KGaA, Darmstadt, Germany 
Chloroform Merck KGaA, Darmstadt, Germany 
Coomassie Brilliant Blue G-250 dye Thermo Fisher Scientific Inc., Waltham, USA 
Crystal violet Merck KGaA, Darmstadt, Germany 
Cupper(II) sulfate pentahydrate 
(CuSo4) 
Merck KGaA, Darmstadt, Germany 
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DAPI Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Destilled Water, DNase/RNase free Life Technologies GmbH, Darmstadt, 
Germany 
DNase I, RNase-free Fisher Scientific GmbH, Schwerte, Germany 
dNTP-Mix Agilent Technologies Inc., Santa Clara, USA 
Dulbecco's Phosphate-Buffered 
Saline (PBS) (1x) (without Ca & Mg) 
PAA Laboratories GmbH, Pasching, Austria 
Ethylendiamintetraacetate (EDTA) Fisher Scientific GmbH, Schwerte, Germany 
EDTA Disodiumsalt Dihydrat 
(nLDL-Oxidation) 
VWR International GmbH, Darmstadt, 
Germany 
Ethanol 96% Sigma-Aldrich Co. LLC, St.Louis, USA 
Ethanol 70% AppliChem GmbH, Darmstadt, Germany 
Fetal bovine serum (FBS) Capricorn Scientific GmbH, Ebsdorfergrund, 
Germany 
Glycerin Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Glycine 99% PA Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Goat serum 
Batch: B11-035 
PAA Laboratories GmbH, Pasching, Austria 
HiPerFect® Transfection Reagent QIAGEN GmbH, Hilden, Germany 
Isopropanol > 99,7% AppliChem GmbH, Darmstadt, Germany 
Methanol Merck KGaA, Darmstadt, Germany 
ß-Mercaptoethanol Merck KGaA, Darmstadt, Germany 
Native human low-density lipoprotein 
(nLDL) 
RayBiotech Inc., Norcross, GA, USA 
Sodium chloride (NaCl) 99,8% Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Sodium dodecyl sulfate (SDS) Pellets 
>99% 
Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Nonident™ P-40 (NP-40) Sigma-Aldrich Co. LLC, St.Louis, USA 
NuPAGE® Antioxidant Invitrogen, Eugene, USA 
NuPAGE® MES 20x  
(SDS Running Buffer) 
Invitrogen, Eugene, USA 
Oil-Red-O-Dye Alfa Aeser GmbH & Co.KG, Karlsruhe, 
Germany 
Oligo (dt)15-Primer Fisher Scientific GmbH, Schwerte, Germany 
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Paraformaldehyde (PFA) Merck KGaA, Darmstadt, Germany 
Penicillin/Streptomycin 100x Capricorn Scientific GmbH, Ebsdorfergrund, 
Germany 
Powdered Milk, blotting-grade, low-in-
fat 
Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
peqGOLD Trifast™ PEQLAB Biotechnologie GmbH, Erlangen, 
Germany 
Phosphate-buffered saline (PBS) 10x 
without Ca2+, Mg2+ 
LONZA Group AG, Basel, Switzerland 
Phosphate-buffered saline (PBS) 1x 
without Ca2+, Mg2+ 
LONZA Group AG, Basel, Switzerland 
Phorbol-12-myristate-13-acetate 
(PMA) 
Sigma-Aldrich Co. LLC, St.Louis, USA 
Protease/Phosphatase Inhibitor 
Cocktail 100x 
Cell Signaling Technology Inc., Danvers, 
MA, USA 
Reaction buffer with MgCl2 (10x) Fisher Scientific GmbH, Schwerte, Germany 
recombinant GDF-15 protein 
#1437 9580 20 
species: human, source: CHO  
provitro AG, Berlin, Germany 
RIPA Lysis Puffer, 10x Cell Signaling Technology Inc., Danvers, 
MA, USA 
RNase Away Molecular BioProducts Inc., San Diego, USA 
RPMI-STA,  
RPMI 1640 with stable Glutamine 
Capricorn Scientific GmbH, Ebsdorfergrund, 
Germany 
RPMI-XRXA 
RPMI 1640, w/o L-Glutamine,  
w/o Phenol Red 
Capricorn Scientific GmbH, Ebsdorfergrund, 
Germany 
Hydrochloric acid 1mol/l Merck KGaA, Darmstadt, Germany 
SigmaFAST™ OPD Peroxidase 
Substrate 
Sigma-Aldrich Co. LLC, St.Louis, USA 
Trinitrobenzene sulfonic acid 
(TNBSA) 
Thermo Fisher Scientific Inc., Waltham, USA 
Tris Base 99,9% PA Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Trypan blue 0,4% Merck KGaA, Darmstadt, Germany 
Triton X-100 Sigma-Aldrich Co. LLC, St.Louis, USA 
Tween® 20 Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
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2.1.4 Buffers and Solutions 
Table 5: Buffers/Solutions in alphabetical order. 
Buffers/Solutions Ingredients 
Blocking Solution (5% milk powder in 
TTBS) 
5 g milk powder 
per 100 ml TTBS 
Coomassie Blue dye solution 
(agarose gel) 
100 mg Coomassie Blue  
25 ml Ethanol (100%) 
5 ml acetic acid 
ad 100 ml aqua dest. 
Destain solution 
(destain Coomassie Blue dye solution 
for agarose gel) 
10 % Acetic acid (100%) 
10 % Ethanol (96%)  
in aqua dest. 
Loading buffer 
(agarose gel) 
0.25 % (w/v) Bromphenol blue 
30 % (v/v) Glycerin 
ad 1 ml aqua dest. 
NuPAGE® MES 1x  
(SDS Page Running Buffer) 
10 ml NuPAGE® 20x MES  
(SDS Page Running Buffer) 
500 µl NuPAGE® Antioxidant 
ad 200 ml aqua dest. 
NuPAGE® 4x loading buffer 
(SDS Page) 
5,6 mM Tris Base 
4,22 mM Tris HCL 
2,77 mM SDS 
20,53 mM EDTA 
43,4 mM Glycerin 
200 µl Bromphenol blue (1%) 
ad 1 ml aqua dest.  
pH 8,5 
add before use 200 mg DTE/ml 
Oil-Red-O stock solution 3 mg/ml Oil-Red-O in 100% isopropanol 
Oil-Red-O working solution 3:2; stock solution:aqua dest. 
RIPA (1x) 
incl. Protease/Phosphatase Inhibitor 
1:10 10x RIPA in aqua dest. 
1:100 Protease/Phosphatase-Inhibitor 
RPMI 1640 culture medium 
for THP-1 cells 
445 ml RPMI 1640 
50 ml FKB (10%) 
5 ml P/S (1%) 
Stripping buffer 
(after Amersham) 
62,5 mM Tris Base in 500 ml aqua dest. 
2% SDS 
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pH 6,7 
add 139,5 µl ß-Mercaptoethanol  
before use 
TAE buffer (50x) 
(agarose gel) 
242 g Tris-Base 
57.1 ml acetic acid 
100 ml 0.5 M EDTA 
ad 1000 ml aqua dest. 
TAE buffer (1x) 
(agarose gel) 
5 ml TAE (50x) 
245 ml aqua dest. 
Transfer buffer (10x) 
(SDS Page) 
0,25 M Tris Base 
1,92 M Glycin 
in 1l aqua dest. 
Transfer buffer (1x) 
(SDS Page) 
800 ml aqua dest. 
100 ml 10x Transfer Puffer 
100 ml Methanol 
Washing buffer (5x) 
(Western Blot) 
1,99 M Tris Base 
2,49 M NaCl 
29,55 mM EDTA 
0,5% Tween 20 
ad 2 l aqua dest. 
pH 7,5 
2.1.5 Used Kits  
Table 6: Used Kits in alphabetical order with ingredients and producer. 
Kit Ingredients Producer 
AceGlow™ 
Chemiluminescence 
Substrate 
• Ace Glow Solution A  
(stabile Peroxid) 
• Ace Glow Solution B 
(Luminol) 
PEQLAB 
Biotechnology 
GmbH, Erlangen, 
Germany 
Affinity Script Multiple 
Temperature 
Reverse 
Transcriptase 
• Affinity Script Multiple 
Temperature Reverse 
Transcriptase 
• 10x Affinity Script RT Puffer 
• 100 mM DTT 
Agilent Technologies 
Inc., Santa Clara, 
USA 
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Agilent RNA 6000 
Nano Kit 
• Agilent RNA 6000 Nano 
Chips 
• Electrode cleaners 
• Spin filters 
• Agilent RNA 6000 Ladder 
• RNA Nano Dye Concentrate 
• Agilent RNA 6000 Nano 
Marker 
• Agilent RNA 6000 Nano Gel 
Matrix 
Agilent Technologies 
Inc., Santa Clara, 
USA  
Brilliant III Ultra-Fast 
SYBR® Green 
QPCR Master Mix 
• 2x Brilliant III Ultra-Fast 
SYBR® Green QPCR Master 
Mix 
• ROX Reference Dye (1mM) 
Agilent Technologies 
Inc., Santa Clara, 
USA 
Cell Meter™ 
Autophagy Assay Kit 
• 500X Autophagy Blue™ 
• Stain Buffer 
• Wash Buffer 
AAT Bioquest® Inc. 
Sunnyval, CA, USA 
Cholesterol / 
Cholesteryl Ester 
Quantification Assay 
Kit (Colorimetric / 
Fluorometric) 
• Cholesterol Assay Buffer 
• Cholesterol Probe 
• Enzyme Mix 
• Cholesterol Esterase 
Abcam plc., 
Cambridge, UK 
DuoSet® ELISA  
Human GDF-15 
• Human GDF-15 Capture 
Antibody 
• Human GDF-15 Detection 
Antibody 
• Human GDF-15 Standard 
• Streptavidin-HRP 
R&D Systems Inc., 
Minneapolis, USA 
FlexiTube 
GeneSolution siRNA 
for GDF-15 
• Hs_GDF15_1 
• Hs_GDF15_2 
• Hs_GDF15_4 
• Hs_GDF15_5 
QIAGEN GmbH, 
Hilden, Germany 
LysoBrite™ Red • 500X LysoBrite™ dye AAT Bioquest® Inc. 
Sunnyval, CA, USA 
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Pierce™ BCA Protein 
Assay Kit 
• Pierce BCA Protein Assay 
Reagent A 
• Pierce BCA Protein Assay 
Reagent B 
Fisher Scientific 
GmbH, Schwerte, 
Germany 
2.1.6 Antibodies  
Table 7: Used Antibodies in alphabetical order.  
Antibody Description  Cat.no Producer Dilution MW 
(kDa) 
Primary antibodies 
anti-alpha 
tubulin 
rabbit anti-alpha 
tubulin antibody 
 Ab4074 Abcam plc., 
Cambridge, 
UK 
1:4000 50 
anti-ATG12 monoclonal rabbit  
anti-ATG12 
antibody 
 D88H11 Cell Signaling 
Technology, 
Inc., Danvers, 
MA, USA 
1:1000 16  
(free 
ATG12) 
60 
(ATG12
-ATG5) 
anti-ATG5 monoclonal rabbit  
anti-ATG5 
antibody 
 D5F5U Cell Signaling 
Technology, 
Inc., Danvers, 
MA, USA 
1:1000 56 
anti-Beclin-1 monoclonal rabbit 
anti-Beclin-1 
antibody 
 D40C5 Cell Signaling 
Technology, 
Inc., Danvers, 
MA, USA 
1:1000 60 
anti-mTOR rabbit anti-mTOR 
antibody 
 2972 Cell Signaling 
Technology, 
Inc., Danvers, 
MA, USA 
1:1000 289 
anti-p62 
(SQSTM1) 
monoclonal rabbit 
anti-p62 antibody 
 D5E2 Cell Signaling 
Technology, 
Inc., Danvers, 
MA, USA 
1:1000 62 
anti-p62 
(SQSTM1) 
IF preferred 
monoclonal rabbit 
anti-p62 antibody  
 D10E10 Cell Signaling 
Technology, 
Inc., Danvers, 
MA, USA 
1:400 
(IF) 
 
anti-
phospho-
mTOR 
(Ser2448) 
rabbit anti 
phosphor-mTOR 
(Ser2448) 
antibody 
 2971 Cell Signaling 
Technology, 
Inc., Danvers, 
MA, USA 
1:1000 289 
anti-Lamp-
1/CD107a 
(IF) 
polyclonal rabbit 
anti-Lamp-
1/CD107a 
antibody 
 NB120-
19294 
Novus 
Biologicals, 
LLC, 
Centennial, 
CO, USA 
1:100 
(IF) 
 
Secondary antibodies 
anti-rabbit 
IgG 
donkey anti-rabbit 
IgG, 
 NA9340 GE Healthcare 
Life Science 
1:3000 
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HRP-linked 
F(ab')2-fragment 
Freiburg, 
Germany 
anti-rabbit 
IgG (H+L)  
goat anti-rabbit 
igG, (H+L) 
F(ab’)2-fragment 
Alexa Fluor® 488 
conjugate 
 4412 Cell Signaling 
Technology, 
Inc., Danvers, 
MA, USA 
1:1000 
anti-rabbit 
IgG (H+L)  
goat anti-rabbit 
igG, (H+L) 
F(ab’)2-fragment 
Alexa Fluor® 555 
conjugate 
 
 4413 Cell Signaling 
Technology, 
Inc., Danvers, 
MA, USA 
1:1000 
2.1.7 Primers 
Table 8: Used Primers. All primers were purchased from Qiagen GmbH, Hilden, Germany. 
Gene symbol detected transcript amplicon length Cat.no 
Reference gene    
Actin β, Actβ NM_001101 146 QT00095431 
Gene of interest    
Growth-Differentiation-
Factor 15, GDF-15 
NM_004864 114 QT00082558 
2.1.8 Software 
Table 9: Used Software. 
Equipment Software Company 
Chemiluminescence  
(Evaluation Western Blot) 
Fusion Capture 1609B PEQLAB 
Biotechnologie GmbH, 
Erlangen, Germany 
Confocal laser scanning 
microscope Nikon Eclipse Ti 
NIS Elements  
4.30.01 64-bit 2014 
Nikon GmbH, 
Geschäftsbereich 
Mikroskope, 
Düsseldorf, Germany 
Graphical Illustration Microsoft Excel 2016  Microsoft Corporation, 
Redmond, USA 
Java-based image processing Image J 1.52a National Institutes of 
Health, Bethesda, USA 
Light microscope images AxioVision Release 4.8.2 Carl Zeiss AG, 
Oberkochen, Germany 
Real Time PCR MxPro QPCR Software Agilent Technologies 
Inc., Santa Clara, USA 
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Statistical analyses Sigma Plot 12.0 Systet Software Inc., 
Chicago, USA 
2.1.9 THP-1 cells 
Cell line:  
DSMZ no.:  
Species:  
Cell type:  
Origin:  
 
 
  
 
 
Reference(s): 
Biosafety level: 
Permissions and Restrictions: 
Morphology: 
Medium: 
 
Incubation: 
Doubing Time: 
Harvest: 
Storage: 
THP-1  
ACC 16  
human (Homo sapiens)  
acute monocytic leukemia  
established from the peripheral blood of a 1-year-old 
boy with acute monocytic leukemia (AML) at relapse 
in 1978; the cells can be used for induction of 
differentiation studies;  
the cells were described to produce lysozyme and to 
be phagocytic; carries t(9;11)(p21;q23) leading to 
MLL-MLLT3 (MLL-AF9) fusion gene  
14493, 15021, 15022, 18187 
 
1  
A 
round, single cells in suspension, partly in clusters  
90% RPMI 1640 + 10% heat-inactivated FBS  
+ 1% Pen/Strep 
at 37 °C with 5% CO2  
ca. 35-50 hours  
saturation density at about 1.0 x 106 cells/ml  
frozen with 70% medium, 20% FBS, 10% DMSO  
Source: DSMZ, 2020 
2.2 Methods  
2.2.1 Cell Culture 
All experiments were performed under a sterile working bench. 
2.2.1.1 Defrosting and culturing of THP-1 monocytes 
THP-1 cells, which were stored in liquid nitrogen, were quickly defrosted by placing them 
in the cell incubator at 37°C. Then, the cells were resuspended in 10 ml RPMI 1640 cell 
medium with L-Glutamine, which was supplemented with 10% heat-inactivated FBS, 100 
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U/ml Penicillin and 0.1 mg/ml Streptomycin. After centrifugation at 250 x g for 10 min at 
room temperature (RT), the supernatant was removed, the cell pellet resuspended in 1 
ml fresh medium and transferred into a 25 cm2 flask containing 9 ml medium. Thereafter 
the cell culture was maintained at 37°C in a humified cell incubator at an atmosphere 
with 5% CO2. 
2.2.1.2 Cell splitting and cell counting 
THP-1 cells were cultivated until they reached 1x106 cells/ml. Then, the cell suspension 
was transferred into a 50 ml tube and centrifuged for 10 min at 250 x g and RT. After 
discarding the supernatant, the cells were resuspended in 10 ml medium. For further 
cultivation or experimental implementation, the exact cell number in the suspension was 
determined using a C-Chip Neubauer-improved disposable counting chamber. 
Therefore, 10 µl cell suspension was mixed with trypan blue (1:10) and incubated for 1 
min at RT. This diazo dye stains dead cells blue, while living cells do not absorb the dye. 
Subsequently, 10 µl of the mixture was placed in a disposable counting chamber (C-Chip 
Neubauer improved) and the cell count was determined under the light microscope. For 
the determination of the cell count, living cells (trypan blue negative) were counted in the 
four corner squares and the cell concentration was calculated with the following formula:  
living cells in 4 squares
4 [squares]
 x 10 [dilution fator] x 10.000 [chamber factor] = cells/ml 
Thereafter, the appropriate cell number could be calculated and used for experiments. 
For further cultivation, the amount of 1x105 cells/ml were suspended in 1 ml medium and 
put into a new cell culture flask (75cm2) together with 30 ml fresh medium, cultivated at 
37°C and 5% CO2. 
2.2.1.3 Differentiation of THP-1 monocytes into THP-1 MФ 
To investigate the influence of GDF-15 on THP-1 MФ, THP-1 monocytes were 
differentiated into MФ. The differentiation was induced by exposing THP-1 monocytes to 
80 nM PMA for 72h. Therefore, 3.5x105 cells/ml were seeded in 96-well, 24-well or 12-
well plates, depending on the experiment to be performed. Then, the cells were cultured 
in culture medium (RPMI 1640 + 10% FKS + 1% P/S) supplemented with 80nm PMA for 
72h. Afterwards, a 24h resting-period was performed in culture medium. The 
differentiated cells now adhered to the bottom of the culture plate and usually showed 
an elongated, flattened morphology. Non-adherent and therefore, non-differentiated cells 
were removed during medium change. 
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2.2.1.4 Transfection of THP-1 MФ 
To investigate the GDF-15 dependent MФ autophagy and lipid homeostasis, the GDF-
15 protein level was decreased in THP-1 MФ by transfecting the cells with small 
interfering RNA (siRNA) against GDF-15. After the resting period, the differentiated THP-
1 MФ were transfected with 4 different siRNAs directed against 4 different sequences of 
the GDF-15 mRNA to increase the efficacy of GDF-15 mRNA degradation. The AllStars 
Negative Control siRNA (Qiagen) was used as negative control. Since this siRNA has 
no known homologies to any mammalian gene, the gene expression should not be 
affected by this siRNA. The AllStars Hs Cell Death siRNA (Qiagen) was used as positive 
control, degrading mRNA of ubiquitously expressed survival genes and thus, inducing 
cell death. 50nM of the corresponding siRNA were dissolved in 200 µl medium without 
supplements per well (for a 24-well plate) together with 3 µl HiPerFect transfection 
reagent (transfection-solution). After vortexing for 10 s, the solutions were incubated at 
RT for 5-10 min. Before transfection, the cells were washed with medium without 
supplements. Thereafter transfection-solution was added to the cells dropwise. 
Afterwards, the transfected THP-1 MФ were incubated for 6h at 37°C and 5% CO2. After 
6h, 300 µl medium per well, supplemented with FBS, but without P/S were added. 
Thereafter, the cells remained in the incubator for 48h. Afterwards, the cells transfected 
with AllStars Hs Cell Death siRNA were evaluated by light microscopy to verify the 
successful transfection by identifying dead cells. Subsequently, the cells transfected with 
i) siRNA against GDF-15 or ii) siRNA negative control were washed and further exposed 
to oxLDL, described in the next chapter. 
2.2.1.5 Lipoprotein- and rGDF-15-exposure 
After transfection, cells were washed with medium to remove the transfection reagents. 
Thereafter, THP-1 MФ were exposed to 50 µg/ml oxLDL to induce foam cell formation 
or cells were left in culture medium for 4h. Another experimental approach to investigate 
GDF-15 dependent MФ autophagy and lipid homeostasis was the augmentation of the 
GDF-15 protein level with recombinant GDF-15 (rGDF-15). In this experimental setting, 
THP-1 MФ were exposed to 50 µg/ml oxLDL and/or rGDF-15 for 4h, immediately after 
PMA-induced differentiation and the 24h resting-period. After 4h exposure-time, the cells 
were harvested or fixed, depending on the following experiments. An overview of the 
experimental setting is depicted in Figure 4. 
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Figure 4: Experimental Setting. (A) To decrease the GDF-15 protein level, PMA-differentiated THP-1 MФ 
were transfected with siRNA against GDF-15 (siGDF-15) or negative control (nsiGDF-15). Thereafter,  
THP-1 MФ remained in culture medium or were exposed to 50 µg/ml oxLDL to induce foam cell formation. 
(B) In order to increase the GDF-15 protein level, THP-1 MФ were exposed to 1.0 µg/ml or 1.5 µg/ml 
recombinant (r)GDF-15. To induce foam cell formation in THP-1 MФ with elevated GDF-15 protein levels, 
cells were incubated with the combination of 1.0 µg/ml or 1.5 µg/ml rGDF-15 and 50 µg/ml oxLDL. As 
controls, THP-1 MФ were incubated with 50 µg/ml oxLDL alone or cells were left in culture medium (0 µg/ml 
rGDF-15). Thereafter, THP-1 MФ were.harvested or fixed, depending on the further experimental procedure.  
2.2.2 Molecular Biology 
2.2.2.1 RNA preparation with PeqGold Trifast 
After transfection and lipoprotein-exposure, THP-1 MФ were harvested and the RNA was 
isolated. In order to avoid contamination and degradation of the RNA, the tools used and 
the working surface were firstly cleaned with RNase AWAY. After removal of the 
supernatant, 200 µl Trifast per well (12-well-plate) was added under a fume hood. After 
an incubation period of 2-3 min on ice, the cells were scraped off with a cell scraper and 
transferred to an RNase free tube on ice. After 5 min incubation at RT, 40 µl chloroform 
were added and the tube was repeatedly inverted for 15s. By centrifugation at 4°C and 
13 000 rpm for 5 min (Heraeus ™ Biofuge PrimoR) the homogenate was separated into 
3 phases. The aqueous, upper phase contained the RNA, the interphase contained the 
DNA and the organic, lower phase contained the proteins. After transferring the upper 
phase into a new tube, 100 µl isopropanol was added. After thorough mixing, the 
Material and Methods 33 
samples were left on ice for 15 min, followed by centrifugation for 30 min at 13 000 rpm 
and 4°C to precipitate the RNA. The RNA pellet was carefully freed from the supernatant 
and washed twice with 500 µl 70% ethanol. After addition of ethanol, the samples were 
centrifuged again for 5 min at 13 000 rpm and 4°C (Heraeus ™ Biofuge PrimoR). After 
the last washing step and removal of the supernatant, the pellet was air dried under the 
fume hood. As soon as the residual ethanol completely evaporated the pellet was 
carefully dissolved by pipetting up and down several times with 15 µl H2O including 
RiboLock (1 µl RiboLock added to 100 µl H2O). For complete dissolution of the RNA the 
samples were incubated for 10 min at 60°C on the heating block. After dissolution the 
RNA was stored at -80°C until further processing. 
2.2.2.2 RNA concentration measurement with NanoDrop 
The RNA concentration was determined by absorption measurement at 260 nm 
wavelength, using NanoDrop 200C. Since the absorption unit corresponds to 40 µg 
ssRNA/ml, the concentration was determined using the following formula:  
c [
µg RNA
ml
] = A(260) x 40 
For measurement, 1µl RNA was applied and measured twice in a row. Furthermore, the 
absorption ratio A260/A280 provides information about the purity of the sample. For pure 
RNA the ratio should be between 1.9-2.1. 
2.2.2.3 RNA integrity-control with Bioanalyzer 
The integrity of the isolated RNA was determined using the Agilent RNA 6000 Nano Kit 
with the Agilent 2100 Bioanalyzer. With this technique, based on the principle of capillary 
electrophoresis, the RNA samples are separated according to their fragment size by the 
molecular sieve effect, using a polymer. Based on the ratio of the ribosomal subunit 28s 
to 18s rRNA, the software determines a RIN value between 1 (completely degraded 
RNA) and 10 (completely intact RNA). For the nanochip analysis, all RNA samples (1μl) 
previously had to be adjusted with RNase-free water to a concentration between 5 ng/μl 
and 500 ng/μl. Additionally, the RNA Ladder was heat-denatured for 2 min at 70°C and 
stored in 1.3 µl portions at -80°C until usage. Furthermore, 550 µl of the  
Agilent 6000 Nano Gel Matrix were centrifuged through a filter for 10 min at 1500 x g. 
Thereafter, the Matrix was aliquoted in 65 µl portions and stored at 4°C for up to 4 weeks. 
Before loading, the chip, the solutions (RNA Nano Dye Concentrate (in the dark), Agilent 
RNA 6000 Nano Marker and the gel matrix) were equilibrated at RT. Immediately before 
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loading of the chip, 1 µl dye solution was pipetted onto 65 µl gel matrix and centrifuged 
for 10 min at 13.000 rpm. After the Gel-Dye-Mix was pipetted into the chip, an evenly 
distribution of the solution was achieved by using the Priming Station. Thereafter,  
5 µl RNA Nano Marker were pipetted into each sample well. Then 1 µl RNA Ladder or  
1 µl RNA sample were added. After vortexing the loaded chip for 1 min at 2000 rpm, the 
analysis was performed with the Bioanalyzer and evaluated with the included software. 
Only RNA samples with a RIN value >7 were used for subsequent experiments. 
2.2.2.4 DNA digestion with DNAse I 
In order to remove any residual DNA from the RNA samples, a DNA digestion using the 
enzyme DNase I was performed. For this purpose, 1 µg of isolated RNA was used and 
a digestion-mix was prepared according to the pipetting scheme in Table 10. The 
reaction buffer together with DNase I was prepared as a master mix and pipetted to the 
1 µg RNA sample. After mixing and a short centrifugation, the samples were incubated 
for 30 min at 37°C. To stop the reaction, 1 µl EDTA per sample was added and heated 
to 65°C for 10 min.  
Table 10: Pipetting scheme for a DNAse digestion. 
Volume components 
1 µg isolated RNA 
1 µl 10x reaction buffer with 
MgCl2 
1.5 µl DNase I enzyme 
Ad 10 µl H2O 
 
2.2.2.5 cDNA synthesis 
For further analysis, the RNA was transcribed into cDNA. The pool of copies produced 
in this way is much more stable and the cDNA molecules can subsequently serve as 
templates for a polymerase. This enables the amplification of specific cDNA molecules 
and provides information on gene expression. The standard pipetting scheme of a  
20 μl mix is shown in Table 11. In order to avoid concentration variations, master mixes 
(I. and II.) were prepared, which contained all reagents except RNA and H2O.  
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Table 11: Pipette scheme for a cDNA synthesis. 
 volume components 
I. 1 µg RNA  
 1 µl Oligo dT18 
 ad 13.7 µl H2O 
mix – centrifuge shortly – 5 min at 65°C 
10 min at 24°C 
II. 2 µl 10x A.Script Buffer 
 2 µl 100 mM DTT 
 0,8 µl 100 mM dNTP-Mix 
 1 µl A. Script Reverse 
Transcriptase 
 0,5 µl RiboLock 
mix – centrifuge shortly – 1h at 42°C 
heat-deactivate at 70°C for 15 min 
2.2.2.6 Real Time-quantitative Polymerase Chain Reaction (RT-qPCR) 
Real Time-quantitative PCR is an amplification method for nucleic acids, that allows the 
quantification of the cDNA obtained. The quantification is performed by fluorescence 
measurements, which are recorded in real time during a PCR cycle. The fluorescent dye 
used (here SYBR Green) intercalates into the double helix by binding into the small 
groove between the bases. Since the amount of amplified cDNA increases from cycle to 
cycle, the increase in stained cDNA correlates with the increase in fluorescence, which 
is measured at the end of the elongation phase. Elongation is followed by denaturation, 
whereby the SYBR Green I dye is released from the DNA. The free dye molecules emit 
a low background fluorescence, which is later subtracted from the actual signal by the 
PCR software. To control the product specificity of the SYBR Green I PCR, a melting 
temperature analysis is performed after each PCR. Thereby, the amplifications are 
melted by a continuous temperature increase, where the melting temperature is 
determined by the length, sequence and GC-content of the DNA double strand. If the 
melting temperature curve shows more than one peak, usually at a lower temperature 
than that of the target gene, non-specific products or primer dimers were amplified. Since 
only under optimal conditions, a constant doubling of the initial amount of cDNA takes 
place in the exponential (log-linear) phase of each cycle, it is possible to calculate the 
product amount (N) using the initial amount (N0) and the PCR efficiency (E), as well as 
the number of PCR cycles (CT):  
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N = N0 * EcT 
This equation can be linearized by logarithmization: 
log N = log N0 + CT * log E 
After further reshaping, the equation of the standard curve is obtained: 
CT = - 
1
log E
 * log N0 + 
log N
log E
 
The preparation of a 96-well PCR plate was carried out under a PCR workstation, 
previously irradiated with UV light. The cDNA was first diluted 1:10 with H2O. The cDNA 
pool, which served as the standard for the PCR, was diluted 1:10 - 1:320 in a serial 
dilution. After pipetting 10 µl of the master mix (Table 12) per well, 5 µl cDNA sample 
was added in duplicate. 
Table 12: Master mix for PCR analysis. 
Volume Reagent 
7,5 µl SYBR Green Mix 
1,5 µl Primer-Mix 
1 µl H2O 
After sealing, the PCR plate was briefly centrifuged. For PCR the following thermal profile 
was used (Table 13). 
Table 13: Thermal profile for a RT-qPCR. 
Time Temperature 
3 min 95°C 
10 s 95°C          x 40 
20 s 60°C 
Dissociation curve 
1 min 95°C 
30 s 55°C 
30 s 95°C 
Material and Methods 37 
Using the MxPro qPCR software (Agilent Technologies), an average value was 
calculated from the double determination of the CT value. Thereafter, the corresponding 
value was normalized with the determined actin-ß value of the cDNA sample. For 
calculations, the value of the nsiGDF-15 MФ remaining in culture medium for 4h were 
set as 100% GDF-15 expression, in order to detect any expression differences in the 
differently treated samples. 
2.2.3 Biochemistry 
2.2.3.1 Protein extraction with RIPA 
All subsequent steps were performed on ice. After exposing (transfected) THP-1 MФ to 
oxLDL (and/or rGDF-15), the supernatant was removed and the cells were washed with 
ice cold 1x PBS. Thereafter, cell lysis was performed with 150 µl 1x RIPA  
(incl. protease/phosphatase inhibitor) (12-well plate). After 5 min incubation on ice, the 
cells were carefully scraped off with a cell scraper and transferred to a fresh tube. The 
cell lysates were homogenized for 3 min in an ultrasonic bath in ice water. After 
centrifugation at 13 000 rpm and 4°C for 10 min (Heraeus ™ Biofuge PrimoR), the 
protein-containing supernatant was removed from the pellet, consisting of cell debris. 
After protein extraction, the protein concentration was determined by BCA and proteins 
could be stored at -20°C. 
2.2.3.2 Protein concentration measurement with BCA  
The bicichoninic acid assay is a spectrophotometric method for determining protein 
concentrations in solution, due to the reduction of a cupric cation (Cu2+ to Cu1+) initiated 
by proteins in an alkaline medium. The arisen cuprous cations (Cu1+) can be colorimetric 
detected by bicichoninic acid, which binds to the emerging copper cations (Cu1+) and 
induce a colorimetric switch. Thereby, the total protein concentration can be determined 
by comparison to a protein standard. First, copper chelates with the peptide bonds in an 
alkaline medium to a light blue complex, called biuret reaction. The bicichoninic acid then 
chelates with the reduced Cu1+ ions, resulting in a reddish colour change. The newly 
formed BCA-Cu1+ complex has a strong linear absorption with increasing protein 
concentration, which can be measured at 562 nm wavelength. For protein quantification, 
the absorbance of sample and BSA standard was measured in duplicates on a  
96-well plate. Therefore 10 µl samples or BSA standard (0, 25, 125, 250, 500, 1000, 
1500 and 2000 µg/ml), together with 200 µl BCA working reagent (50:1, Reagent A:B) 
were incubated for 30 min in the dark at 37°C. Thereafter, the measurement was 
performed in the Tecan Sunrise Microplate Reader at 562 nm, with reference 0 nm. The 
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generated BSA standard curve (Figure 5) was used to determine the protein 
concentration by linear interpolation. 
 
Figure 5: BCA standard curve. Representative BCA standard curve. With the protein standard (0, 25, 125, 
250, 500, 1000, 1500 and 2000 µg/ml) the generated standard curve can be used to calculate the protein 
concentration of the samples. 
2.2.3.3 GDF-15 Elisa  
To quantify the amount of GDF-15 protein in the protein samples, a DuoSet® ELISA for 
human GDF-15 was used. Therefore, the GDF-15 antigen specific capture antibody was 
diluted to a working concentration of 4.0 µg/ml in 1xPBS and 100 µl/well were pipetted 
into a MaxiSorp 96-well plate and incubated over night at 4°C. After washing three times 
with 400 µl 0.05% Tween-20® in 1xPBS (washing buffer) using the HydroFlex Elisa-
Washer, blocking of unspecific binding sites of the capture antibody was performed with 
1% BSA in PBS for 1h at RT. Thereafter, three washing steps (washing buffer) were 
performed. Samples were prepared, using 5 µg total protein in 100 µl 1xRIPA. The 
standard was prepared according to the manufacturer’s instructions in 1xRIPA. After 
washing, the samples or standard were applied (100 µl/well) and incubated for 2h at RT. 
Another three washing steps were followed by incubation with 100 µl detection antibody, 
prepared according to the manufacturer’s’ instructions for 2h at RT. Since the detection 
antibody is biotinylated, streptavidin was used to bind to the biotin of the detection 
antibody and streptavidin (1:200 diluted in 1% BSA in PBS; 100 µl/well) is covalently 
bound to the horse radish peroxidase (HRP). After 20 min incubation in the dark, three 
washing steps were followed by two washes with 300 µl distilled water. To detect the 
peroxidase activity, 100 µl of the soluble substrate (Sigma Fast OPD tablets dissolved in 
50 ml distilled water) was added and incubated for 30 min in the dark at RT. During this 
time the substrate is oxidized by the HRP, causing a characteristic change in the 
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substrates’ structure, which is now photometrically detectable. This reaction was stopped 
using 25 µl/well 3M HCL, thereafter the absorbance was measured at  
490 nm wavelength, with a reference at 655 nm. The generated standard curve  
(Figure 6), was used to determine the GDF-15 protein concentration by linear 
interpolation. 
. 
 
Figure 6: GDF-15 Elisa standard curve. Representative GDF-15 Elisa standard curve. With the protein 
standard (8, 16, 32, 64, 125, 250 and 500 pg/ml) the generated standard curve can be used to calculate the 
GDF-15 protein concentration of the samples. 
2.2.3.4 SDS PAGE 
Using a 4-12% Bis-Tris SDS-PAGE, proteins can be separated according to their 
molecular weight. The used gel consists of polymerized acrylamide, where cross-linked 
polymers form a tight network, through which the proteins move to the anode, when 
voltage is applied. By adding SDS, an anionic detergent, the samples are uniformly 
negatively charged, so that the movement of the proteins in the electric field towards the 
anode is exclusively influenced by their molecular weight. Besides SDS, the sample 
buffer also contains DTE to reduce disulfide bridges and bromophenol blue to make the 
running front of the proteins more visible. In this work, 20 µg protein were mixed with  
1x NuPAGE® sample buffer and denatured for 5 min at 95°C on a heating block, then 
put on ice for 5 min for renaturation. As running buffer, 1x MES (Table 5), including 
NuPAGE® antioxidant (ratio 1:4), was used. The renatured samples or the  
peqGOLD marker (IV or VI) were pipetted into the gel pockets and were separated in the 
gel at 200 V for 30-45 min. 
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2.2.3.5 Western Blot Analysis  
After protein separation, the proteins were transferred from the gel to a 0.45 µm 
nitrocellulose membrane through an electric field. Therefore, two Whatman-Papers (8cm 
x 9cm), previously soaked in 1x transfer buffer (Table 5), were inserted into the blotting 
cassette (white side). Then, the moistened (1x transfer buffer) nitrocellulose membrane 
(7cm x 8cm) was applied, followed by the SDS gel and finally two more moistened 
Whatman-Papers were added and the blotting cassettes closed (black side). The blotting 
cassette was placed into the Mini Trans-Blot® Cell and filled with 1x transfer buffer. The 
transfer was carried out at 35 mA overnight.  
Subsequently, protein detection was performed using specific antibodies (Table 7). For 
this purpose, the membrane was blocked twice for 30 min at RT in blocking solution 
(Table 5). The incubation of the membrane with primary antibody (diluted in blocking 
solution) was performed overnight at 4°C (Table 7). After incubation, the membrane was 
washed three times for 10 min in 1x washing buffer. Then, the incubation with the 
corresponding secondary antibody (diluted in blocking solution) (Table 7) was performed 
for 1h, followed by another three washing steps for 10 min. 
The specific protein bands could be detected using HRP, which is coupled to the 
secondary antibody. HRP catalyses the oxidation of luminol by hydrogen peroxide. The 
end product of this reaction causes chemiluminescence. The strength of the emitted light 
is proportional to the amount of bound antibody and thus to the amount of protein. 
AceGlow Chemiluminescence Reagent A and B were added 1:1 to the membrane and 
incubated in the dark for 5 min. The detection of the protein bands was carried out using 
the Fusion-SL Advanced™ Imaging System according to the manufacturer's 
specifications. The protein band-intensity was quantified using ImageJ software 
(National Institutes of Health, USA) and normalized against α-tubulin. 
2.2.3.6 Membrane stripping 
After protein detection, the membrane was washed again three times for 10 min with 
washing buffer. Then, 7 µl ß-mercaptoethanol per 1 ml stripping buffer was mixed and 
added to the membrane (total volume 20 ml). The membrane was then freed from bound 
antibodies for 30 min at 60°C in the Hybridization Oven MK II. After another wash cycle 
(3 x 10 min) the membrane was used for further protein detection. Per membrane a 
maximum of two stripping-cycles were performed. 
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2.2.3.7 Immunofluorescence 
To quantify p62 and Lamp-1 accumulation in THP-1 MФ, immunofluorescence staining 
was performed. For this purpose, THP-1 cells were seeded in a 96-well plate, 
differentiated, transfected and stimulated for 4h (Figure 4). Subsequently, the medium 
was aspirated and cells were washed with 1xPBS. MФ were fixed with ice-cold methanol 
(200 µl/well) for 10 min. After washing the cells with 1xPBS, MФ were permeabilized with 
0.1% Triton X-100 in 1xPBS (100 µl/well) for 15 min. After another washing step with 
1xPBS, blocking was carried out with 2% goat serum in 1xPBS (200 µl/well) for 30 min 
at RT. Thereafter, the primary antibody against p62 or Lamp-1 was diluted in 1xPBS as 
indicated in Table 7 (100 µl/well). Incubation was carried out over night at 4°C. 
Subsequently, cells were washed with 0.1% Triton X-100 in 1xPBS (100 µl/well). The 
respective secondary antibody conjugated with AlexaFluor® 488 or Alexafluor® 555 was 
diluted in 1xPBS, also containing Dapi (1:1000) or DNA staining. After incubation for 1h 
in the dark at RT, cells were washed with 0.1% Triton X-100 in 1xPBS (100 µl/well) and 
finally left in 1xPBS (100 µl/well) during fluorescence detection with the confocal laser 
scanning microscope Nikon Eclipse Ti. The quantification of the Lamp-1 or p62 
accumulation was performed using ImageJ software (National Institutes of Health, USA).  
2.2.3.8 Oil-Red-O-Staining  
To quantify the lipid storage of MФ after exposure to lipoproteins, an ORO staining was 
performed. For this purpose, THP-1 cells were seeded in a 96-well plate, differentiated 
into MФ and incubated as depicted in Figure 4. Subsequently, the medium was aspirated 
and the cells were washed three times with 300 µl medium to remove the respective 
stimulants. The cells were then fixed with 100 µl 10% PFA and incubated for 20 min at 
RT. Afterwards cells were washed twice (300 µl/well) with 1xPBS and once with aqua 
dest. (300 µl/well). Oil-Red-O working solution (Table 5) (100 µl/well), a red staining azo 
dye, was used to stain intracellular triglycerides. After 5 min incubation, the dye was 
removed and the cells were washed three times with 300 µl distilled water. Before 
removing the distilled water for the last time, the staining was verified with the  
Nikon Eclipse TS 100 Invert Microscope. After removal of the distilled water, the dye was 
eluted again with 100% isopropanol (100 µl/well) and absorbance was determined, using 
the Tecan Sunrise Microplate Reader at 595 nm with reference at 655 nm wavelength. 
As blank 100 µl/well 100% isopropanol was applied as triplicate to wells without cells. 
Thereafter, the cells were washed twice with 1x PBS (300 µl/well), twice with  
0.1% Triton X-100 in 1x PBS (200 µl/well) and twice with aqua dest. (200 µl/well) and 
dried for 5 min at RT Afterwards, the cells were stained with previously filtered crystal 
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violet (100 µl/well). After 30 min incubation at room temperature, the cells were stained 
twice with 1x PBS (200 µl/well) and six times with Aqua dist. (200 µl/well) six times. The 
dye was dissolved from the cells with 1% SDS in 1x PBS (100 µl/well) for 30 min. The 
amount of eluted dye was then measured in the Elisa Microplate Reader at 595nm with 
a reference at 655nm. The blank value was measured with 1% SDS in PBS. The data of 
the ORO staining were normalized with the values of the crystal violet staining. The 
percentage of lipid deposition was then calculated by reference to the control as  
100% value. 
2.2.3.9 Autophagy activity assay  
To measure the autophagy activity in THP-1 MФ with enhanced or decreased GDF-15 
protein level, cells were seeded in a Lumox® 96-well plate. After exposure of 
(transfected) THP-1 MФ to oxLDL (and/or rGDF-15) for 4h, the cells were washed with 
RPMI culture medium. The Cell Meter™ Autophagy Assay Kit (AAT Bioquest®) was 
used to measure autophagy activity. Since the included Autophagy Blue™ accumulates 
in autophagosomes, its fluorescence intensity correlates with the number of intracellular 
autophagosomes and thereby the autophagy activity can be measured. The Autophagy 
Blue™ working solution was prepared according to the manufacturer’s instructions and 
100 µl were added into each well. Thereafter, the cells were incubated at 37°C and  
5% CO2 for 20 min, followed by washing the cells with the manufacturer washing buffer 
for four times. For the measurement, the cells remained in the washing buffer. The 
fluorescence intensity was determined using the Cytation™ 3 microplate reader with 
Ex/Em at 333/518 nm wavelength. As a blank, washing buffer was applied in triplicate to 
wells without cells. After subtracting the mean blank from each well, the autophagy 
activity of nsiGDF-15 THP-1 MФ or THP-1 MФ, which remained in culture medium for 4h 
was set as 100% autophagy activity.  
2.2.3.10 Lysosome activity assay 
To measure the lysosome activity of THP-1 MФ with enhanced or decreased GDF-15 
protein level, cells were seeded in a Lumox® 96-well plate. The dye LysoBrite™ Red 
(AAT Bioquest®) was used to measure lysosome activity. Since this dye selectively 
accumulates in lysosomes, its fluorescence intensity correlates with the number of 
intracellular lysosomes and thereby the lysosome activity can be measured. The dye 
working solution was prepared by diluting 20 µl of the 500 X LysoBrite™ stock in  
10 ml RPMI medium without Phenol Red and without L-Glutamine. After exposure of 
(transfected) THP-1 MФ to oxLDL (and/or rGDF-15) for 4h, the supernatant was removed 
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and 100 µl/well of the working solution were applied. Thereafter, the cells were incubated 
at 37°C, 5% CO2 for 30 min, followed by washing the cells twice with RPMI medium 
without Phenol Red and without L-Glutamine. For the measurement, the cells remained 
in the RPMI medium without Phenol Red and without L-Glutamine. The fluorescence 
intensity was determined using the Cytation™ 3 microplate reader with Ex/Em at 575/605 
nm wavelength. As a blank, RPMI medium without Phenol Red and without L-Glutamine 
was applied in triplicate to wells without cells. After subtracting the mean blank from each 
well, the lysosome activity of nsiGDF-15 THP-1 MФ or THP-1 MФ, which remained in 
culture medium for 4h was set as 100% lysosome activity.  
2.2.3.11 Cholesterol Assay  
To measure the amount of total cholesterol (TC), cholesteryl esters (CE) and free 
cholesterol (FC), a Cholesterol / Cholesteryl Ester Quantification Assay Kit (Abcam) was 
used. To measure the TC level, cholesterol is oxidized using cholesterol oxidase to 
produce H2O2, which reacts with a sensitive cholesterol probe to produce fluorescence. 
Based on the same principle, the CE level is measured. Prior to the cholesterol oxidation, 
CE is hydrolysed to cholesterol, using cholesterol esterase. The amount of FC is 
obtained by subtraction of CE from TC. Therefore, THP-1 MФ were seeded in  
6-well plates and differentiated as described. After exposure of (transfected) THP-1 MФ 
to oxLDL (and/or rGDF-15) for 4h, cells were washed with ice cold 1xPBS. Afterwards, 
150 µl ice cold 1xPBS were applied and cells were thoroughly scraped off with a cell 
scraper and transferred to a fresh 1.5 ml tube. After centrifugation at 250 x g and 4°C for 
10 min, the supernatant was discarded. The remaining pellet was thoroughly 
resuspended in 100 µl chloroform: isopropanol: NP-40 in the relation 7: 11: 0.1.  
After centrifugation at 15 000 x g and 4°C for 10 min, the supernatant was discarded and 
the pellet was dried overnight. To remove any residual organic solvents, the samples 
were centrifuged in the vacuum concentrator for 30 min. In the meantime, the Cholesterol 
Standard, TC Reaction Mix and FC Reaction Mix were prepared for a duplicate reading, 
according to the manufacturer’s instructions. After removing all solvents, the samples 
were resuspended in 200 µl Assay Buffer. Thereafter, the standard and samples were 
pipetted as duplicate for the TC Mix and for the FC Mix into a 96-well plate. Finally,  
50 µl Total Cholesterol Mix was added to the standard and to the Total Cholesterol 
samples. 50 µl of the Free Cholesterol Mix was only added to the Free Cholesterol 
samples. After incubation at 37 °C for 60 min in the dark, the fluorescence intensity was 
determined using the Cytation™ 3 microplate reader with Ex/Em at 575/587 nm 
wavelength. The generated standard curve (Figure 7) was used to determine the Total 
and Free Cholesterol concentrations by linear interpolation. In subtracting the sample 
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concentration of Free Cholesterol from the concentration of Total Cholesterol, the 
concentration of Cholesteryl esters was determined.  
 
Figure 7: Cholesterol Assay standard curve. Representative Cholesterol Assay standard curve. With the 
cholesterol concentrations (0, 0.1, 0.2, 0.3, 0.4, and 0.5 µg/50 µl), the generated standard curve can be used 
to calculate the Total and Free Cholesterol concentration of the samples. 
2.2.3.12 LDL oxidation 
For oxLDL-generation, nLDL was suspended in endotoxin-free 1x PBS without Ca2+ and 
Mg2+ to a final concentration of 1 mg protein/ml. Dialyzing of nLDL was performed using 
Slide-A-Lyzer Dialysis Cassettes 7K MWCO in 500 ml endotoxin-free 1x PBS without 
Ca2+ and Mg2+ under constantly stirring for 72 h at 4°C in the dark for removal of EDTA. 
For nLDL oxidation, the Slide-A-Lyzer Dialysis Cassettes 7K MWCO was placed into 500 
ml endotoxin-free 1x PBS without Ca2+ and Mg2+ containing 50 µM CuSO4 and constantly 
stirred for 24 h at RT in the dark. To stop the oxidation, Slide-A-Lyzer Dialysis Cassettes 
7K MWCO were stirred in endotoxin-free 1xPBS without Ca2+ and Mg2+ containing  
50 µM EDTA for 6 h. Thereafter, oxLDL was sterile filtered by using a 0.2 µm filter and 
the concentration was determined using a BCA protein assay as described above. The 
grade of nLDL oxidation was verified using relative electrophoretic mobility (REM) shift 
by agarose gel with nLDL and BSA as reference (Figure 8 A) (Lougheed & Steinbrecher, 
1996). Furthermore, the free amino groups of oxLDL and nLDL were compared, using 
trinitrobenzene sulfonic acid (TNBSA, Thermo Fisher Scientific, Inc.) according to the 
manufacturer’s instruction (Figure 8B) (Foxx et al., 2008). Also, spectrophotometric 
analysis was performed generating an absorbance spectrum for nLDL and oxLDL 
between 400 nm and 700 nm (Tecan Sunrise Microplate Reader) (Figure 8C) (Galle & 
Wanner, 1998.). OxLDL was approved for further experimental usage,  
if at least 40.4% ± 0.65% amino groups were blocked compared to nLDL, an increased 
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REM of 17.5 % ± 3.34% compared to nLDL and the disappearance of the characteristic 
nLDL absorption peaks at 460 and 485 nm were attested.  
 
Figure 8: Methods used to verify nLDL oxidation. (A) Relative electrophoretic mobility (REM) was 
performed by agarose gel electrophoresis with nLDL, BSA and oxLDL (oxidized with 50µM CuSO4). The 
agarose gel was dyed in Coomassie Blue for visualising the different bands. Thereafter the running length 
of every band was measured and compared to the running length of nLDL as reference. (B) Number of 
blocked amino acids in nLDL and oxLDL (oxidized with 50 µM CuSO4) were determined using 
trinitrobenzene sulfonic acid (TNBSA, Thermo Fisher Scientific, Inc.) according to the manufacturer’s 
instructions. (C) Spectrophotometric analysis was performed generating an absorbance spectrum for nLDL 
and oxLDL (oxidized with 50 µM CuSO4) between 400 nm and 700 nm (Tecan Sunrise Microplate Reader). 
nLDL shows a characteristic peak in the absorbance between 460 nm and 485 nm, this peak is lacking when 
nLDL is oxidized. 
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2.2.3.13 Agarose gel electrophoresis (for oxLDL) 
To verify oxidation grad of LDL, agarose gel electrophoresis was performed. Therefore, 
a 1 % agarose gel was prepared by dissolving agarose in 1x TAE buffer. After heating 
the solution for better dissolving, the solution was poured into a gel electrophoresis 
chamber. After cooling, the gel was loaded with oxLDL (8 µl oxLDL with 2 µl loading 
buffer), nLDL (4µl nLDL dialyzed with 4 µl aqua dest. and 2 µl loading buffer) as well as 
BSA (2 µl BSA with 6 µl aqua dest. and 2 µl loading buffer). The gel run at 200 V  
for 30 min. Thereafter, the gel was dyed in Coomassie Blue dye solution for at least  
1 h and destained in destain solution for at least 24 h. Thereafter, the running length of 
the samples was measured and compared. Typically, nLDL shows the shortest, followed 
by oxLDL and BSA runs the furthest, depending on their electrical charge (Figure 9). 
 
Figure 9: 1% agarose gel to verify oxidation grade of oxLDL. 1% agarose gel was loaded with BSA, 
nLDL and oxLDL (oxidized with 50µM CuSO4) and ran at 200 V for 30 min. After dyeing with Coomassie 
Blue and destaining, the running length of the probes was measured and compared with BSA set as 100%. 
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3 Results 
Interested in investigating a potential role of GDF-15 in MΦ autophagy we approached 
bidirectionally. First, a knock-down of GDF-15 in human THP-1 MΦ was assessed using 
small interfering RNAs. Second, THP-1 MΦ were treated with recombinant GDF-15 
(rGDF-15) in concentrations of 1.0 µg/ml and 1.5 µg/ml to elevate the intracellular GDF-
15 protein level. Foam cell formation was induced by treatment with 50 µg/ml oxLDL for 
4h. Thereafter, the expression and accumulation of different autophagy-relevant markers 
as well as the lipid accumulation was assessed.  
3.1 GDF-15 silencing impairs lipid accumulation and autophagic flux in 
human THP-1 MΦ  
3.1.1 Transfection of human THP-1 MΦ with siRNA  
PMA-differentiated human THP-1 MΦ were transfected with siRNA complementary to 
GDF-15 mRNA (siGDF-15). As negative control (nsiGDF-15) siRNA with no known 
homology to any human gene was used. Transfection efficiency was verified by using 
THP-1 MΦ transfected with a cell death-inducing siRNA as positive control. After 48h, 
successful transfection of THP-1 MΦ was assessed via light microscopy. THP-1 MΦ 
showing a round-like shape with intact cell membrane (black arrows) displayed healthy 
cells with no cell death-induction, indicating non-transfected cells. Apoptotic cells (white 
arrows), as indication for successfully induced cell death via transfection, were identified 
by a dissolved cell membrane, releasing cellular debris into the medium (Figure 10). 
 
Figure 10: Light microscopy image of THP-1 MΦ after transfection with AllStars HS Cell Death. PMA-
differentiated THP-1 MΦ were transfected (48h) with AllStars HS Cell Death small interfering RNA, used as 
positive control for assessing transfection efficiency. Black arrows indicate healthy cells, white arrows 
indicate apoptotic cells. Scale bars 20µM. 
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After 48h transfection, foam cell formation was induced by exposing siGDF-15 MΦ and 
nsiGDF-15 MΦ to 50 µg/ml oxLDL for 4h. As control, siGDF-15 MΦ or nsiGDF-15 MΦ 
were incubated in medium alone. siGDF-15 MΦ incubated in medium showed a 
significant (p < 0.001) -75% decreased GDF-15 mRNA level, whereas siGDF-15 MΦ 
incubated with oxLDL showed a -104% (p < 0.001) decreased GDF-15 mRNA level 
compared to equally incubated nsiGDF-15 MΦ (Figure 11 A). OxLDL upregulated the 
GDF-15 mRNA expression in nsiGDF-15 MΦ (35%, p = 0.037), whereas this effect was 
not found in siGDF-15 MΦ (Figure 11 A).  
After incubation of nsiGDF-15 MΦ in medium the GDF-15 protein level was similar to 
that after incubation of nsiGDF-15 MΦ with oxLDL (Figure 11 B). In siGDF-15 MΦ 
incubated in medium, we found a -53% (p = 0.026) reduction of intracellular  
GDF-15 protein in comparison to nsiGDF-15 MΦ incubated in medium (Figure 11 B). 
Furthermore, after incubation of siGDF-15 MΦ with oxLDL, the intracellular  
GDF-15 protein level was -58% (p = 0.001) decreased compared to oxLDL-incubated 
nsiGDF-15 MΦ (Figure 11 B).  
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Figure 11: GDF-15 mRNA and protein levels in nsiGDF-15 and siGDF-15 THP-1 MΦ after exposure to 
oxLDL or after incubation in medium. (A) GDF-15 mRNA level (in % of nsiGDF-15 MΦ incubated in 
medium = 100%) in nsiGDF-15 / siGDF-15 MΦ was determined using RT-qPCR and normalized against 
GAPDH. Three independent experiments were performed. (B) Intracellular GDF-15 levels (pg/µg total 
protein) determined by ELISA [OD490/655]. Six independent experiments were performed. Data are presented 
as mean ± SEM. *p < 0.05, ***p < 0.001 significance vs. nsiGDF-15 MΦ incubated in medium, #p < 0.05, 
###p < 0.001 significance vs. nsiGDF-15 MΦ + 50 µg/ml oxLDL. Student-Newman-Keuls test. Data published 
in Ackermann et al., 2019b. 
3.1.2 GDF-15 silencing decreases lipid burden although cellular cholesterol 
levels remain unaltered 
Modified LDL, such as oxLDL, is assumed as the main lipoprotein to cause foam cell 
formation, a critical step in the initiation of atherosclerosis (reviewed in Chistiakov et al., 
2017). The induction of foam cell formation was examined using Oil-Red-O-staining, 
detecting neutral cell lipids. The successful lipid staining was controlled by light 
microscopy, showing red-colored lipid droplets within the cells (Figure 12 A-D). Exposure 
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to oxLDL caused an increase of 29% (p < 0.05) in the lipid content of nsiGDF-15 MΦ 
compared to nsiGDF-15 MΦ incubated in medium (Figure 12 E). Additionally, treatment 
of siGDF-15 MΦ with oxLDL increased the lipid content about 30% (p < 0.05) in 
comparison to siGDF-15 MΦ incubated in medium (Figure 12 E). Analyzation of the lipid 
content in siGDF-15 MΦ incubated in medium showed a -19% (p < 0.05) decrease 
compared to nsiGDF-15 MΦ incubated in medium, whereas siGDF-15 MΦ exposed to 
oxLDL showed -18% (p < 0.05) reduction in the lipid content compared to nsiGDF-15 
MΦ exposed to oxLDL (Figure 12 E).   
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Figure 12: Lipid accumulation in nsiGDF-15 and siGDF-15 THP-1 MΦ after exposure to oxLDL or after 
incubation in medium. (A-D) Representative images of Oil-Red-O-stained nsiGDF-15 / siGDF-15 THP-1 
MΦ. Black arrows indicate lipid-loaded cells. Scale bars 20µm. (E) Lipid accumulation (in % of nsiGDF-15 
MΦ incubated in medium = 100%) measured by Oil-Red-O-staining after isopropanol elution [OD510]. Seven 
independent experiments were performed. Data are presented as mean ± SEM. *p < 0.05 significance vs. 
nsiGDF-15 MΦ incubated in medium, #p < 0.05 significance vs. nsiGDF-15 MΦ + 50 µg /ml oxLDL, +p < 0.05 
significance vs. siGDF-15 MΦ incubated in medium. Student-Newman-Keuls test. Data published in 
Ackermann et al., 2019b. 
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Beside the measurement of the influence of GDF-15 on lipid content, the cholesterol 
export was examined by measuring the intracellular cholesterol level (Figure 13). Here, 
total cholesterol (TC), free cholesterol (FC) or cholesteryl ester (CE) levels were similar 
in nsiGDF-15 MΦ or siGDF-15 MΦ with or without 50 µg/ml oxLDL exposure (Figure 13).  
 
Figure 13: Cholesterol levels in nsiGDF-15 and siGDF-15 THP-1 MΦ after exposure to oxLDL or 
incubation in medium. (A) Total cholesterol (TC); (B) free cholesterol (FC); (C) cholesteryl ester (CE) in 
nsiGDF-15 / siGDF-15 THP-1 MΦ. Results are expressed in mg/dl. Four independent experiments were 
performed. Data are presented as mean ± SEM. Data published in Ackermann et al., 2019b. 
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3.1.3 GDF-15 silencing impairs autophagosome formation and reduces 
autophagic activity 
Aiming to investigate a possible impact of GDF-15 on MΦ autophagy, the  
autophagy-relevant proteins ATG5 and ATG12, essential for the phagophore expansion, 
were analyzed. In siGDF-15 MΦ incubated in medium, the ATG5 protein level was 
significantly (p < 0.05) -36% decreased compared to nsiGDF-15 MΦ incubated in medium. 
Also, siGDF-15 MΦ incubated with oxLDL showed a -36% (p < 0.05) reduced  
ATG5 protein level compared to oxLDL-incubated nsiGDF-15 MΦ (Figure 14 A, C). OxLDL 
itself caused no significant changes in the ATG5 protein levels in siGDF-15 MΦ or  
nsiGDF-15 MΦ compared to medium-incubated siGDF-15 MΦ or nsiGDF-15 MΦ  
(Figure 14 A, C). The ATG12 / ATG5-complex protein level decreased about  
-20% (p = 0.003) in siGDF-15 MΦ incubated in medium compared to nsiGDF-15 MΦ 
incubated in medium (Figure 14 B, C). Exposure to oxLDL did not influence the  
ATG12 / ATG5-complex protein level in nsiGDF-15 MΦ or siGDF-15 MΦ compared to 
siGDF-15 MΦ or nsiGDF-15 MΦ incubated in medium (Figure 14 B, C).  
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Figure 14: ATG5 protein and ATG12 / ATG5-complex protein levels in nsiGDF-15 and siGDF-15 THP-
1 MΦ after exposure to oxLDL or incubation in medium. (A) ATG5 and (B) ATG12 / ATG5-complex 
protein levels (in % of nsiGDF-15 MΦ incubated in medium = 100%) in nsiGDF-15 / siGDF-15 THP-1 MΦ. 
ATG5 and ATG12 / ATG5-complex protein was normalized against α-tubulin and quantified with ImageJ. (C) 
Representative Western Blot images. Four (ATG5) and six (ATG12 / ATG5-complex) independent 
experiments were performed. Data are presented as mean ± SEM. *p < 0.05, **p < 0.01 significance vs. 
nsiGDF-15 MΦ incubated in medium, #p < 0.05 significance vs. nsiGDF-15 MΦ + 50 µg/ml oxLDL.  
Holm-Sidak test (ATG5) and Mann-Whitney-U test (ATG12 / ATG5-complex). Data published in Ackermann 
et al., 2019b. 
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Autophagic flux was measured by determination of the p62 protein level  
(Figure 15 A, B). In siGDF-15 MΦ incubated in medium, the p62 protein level decreased 
significantly (p < 0.05) about -23% compared to nsiGDF-15 MΦ incubated in medium. 
Incubation of nsiGDF-15 MΦ or siGDF-15 MΦ with oxLDL significantly (p < 0.05) 
increased the p62 protein level about 60% and 65% compared to nsiGDF-15 MΦ or 
siGDF-15 MΦ incubated in medium (Figure 15 A). 
For additional validation of the autophagic status the intracellular p62 accumulation in 
THP-1 MΦ was measured (Figure 15 C, E-J). After incubation of siGDF-15 MΦ in 
medium, p62 accumulation was reduced by -56% (p < 0.001) compared to  
medium-incubated nsiGDF-15 MΦ (Figure 15 C). Incubation of siGDF-15 MΦ with oxLDL 
decreased the p62 accumulation about -67% (p < 0.029) compared to nsiGDF-15 MΦ 
incubated with oxLDL (Figure 15 C). Upon exposure to oxLDL, the p62 accumulation 
increased about 78% (p < 0.009) in nsiGDF-15 MΦ and 67% (p < 0.001) in  
siGDF-15 MΦ compared to nsiGDF-15 MΦ or siGDF-15 MΦ incubated in medium 
(Figure 15 C). As positive control for autophagy activity induction and therefore  
p62 accumulation initiation, THP-1 MΦ were starved for 4h. Upon starvation THP-1 MΦ 
showed a significantly (p < 0.05) 107% enhanced p62 accumulation compared to 
nsiGDF-15 MΦ incubated in medium (Figure 15 C). Besides the amount of p62 
accumulations, the diameter of these intracellularly accumulated p62 was measured to 
draw conclusions regarding changes in the autophagosome-size (Figure 15 D). Here, 
the diameter of intracellularly accumulated p62 varied from 1.7 to 1.9 µm with no 
significant changes in the accumulation size in medium-incubated or oxLDL-incubated 
nsiGDF-15 MΦ and siGDF-15 MΦ (Figure 15 D). 
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Figure 15: p62 protein level and intracellular p62 accumulation in nsiGDF-15 and siGDF-15 THP-1 MΦ 
after exposure to oxLDL or incubation in medium. (A) p62 protein level (in % of nsiGDF-15 MΦ incubated 
in medium = 100%) in nsiGDF-15 / siGDF-15 THP-1 MΦ. Expression was normalized against α-tubulin and 
quantified with ImageJ. Ten independent experiments were performed. (B) Representative Western Blot 
images for p62 and α-tubulin. (C) p62 accumulations (in % of nsiGDF-15 MΦ incubated in medium = 100%) 
were analyzed with Fiji ImageJ and normalized against DAPI (D) Diameter of intracellularly accumulated 
p62 was measured in µm using Fiji ImageJ. Six independent experiments were performed. Data are 
presented as mean ± SEM. (E-J) Representative immunofluorescence images of p62 accumulations (red) 
and DAPI (blue) double staining, visualized with laser scanning microscopy (Nikon Eclipse). (I) The negative 
control shows DAPI-stained THP-1 MΦ without primary antibody against p62. Scale bars 50 µM. *p < 0.05, 
**p < 0.01 significance vs. nsiGDF-15 MΦ incubated in medium, #p < 0.05 significance vs. nsiGDF-15 MΦ + 
50 µg/ml oxLDL, +p < 0.05, +++p < 0.001 significance vs. siGDF-15 MΦ incubated in medium. Student-
Newman-Keuls test (p62 total protein), TTest and Mann-Whitney-U test (p62 accumulation).  
Data (A-C; E-J) published in Ackermann et al., 2019b. 
Additionally, to the measurement of the p62 protein status, we performed an autophagy 
activity assay in combination with a lysosomal activity assay to determine, whether the 
autophagic flux is intact or impaired. In siGDF-15 MΦ incubated in medium, we found a 
decreased autophagic activity by -22% (p = 0.035) in comparison to nsiGDF-15 MΦ 
incubated in medium (Figure 16 A). This autophagic activity-reduction in siGDF-15 MΦ 
compared to nsiGDF-15 MΦ was not seen after exposure to 50 µg/ml oxLDL. However, 
incubation of nsiGDF-15 MΦ or siGDF-15 MΦ with oxLDL significantly decreased the 
autophagic activity by -41% (p < 0.001) in nsiGDF-15 MΦ and -21% (p = 0.011) in  
siGDF-15 MΦ compared to nsiGDF-15 MΦ or siGDF-15 MΦ incubated in medium 
(Figure 16 A). The lysosomal activity showed no significant changes in medium-
incubated siGDF-15 MΦ compared to medium-incubated nsiGDF-15 MΦ (Figure 16 B). 
After incubation with oxLDL the lysosomal activity was reduced by -20% (p < 0.05) in 
nsiGDF-15 MΦ and siGDF-15 MΦ compared to medium-incubated nsiGDF-15 MΦ or 
siGDF-15 MΦ (Figure 16 B). Starvation, was used as positive control for an induction of 
autophagic and lysosomal activity (Zhou et al., 2013). THP-1 MΦ starved for 4h showed 
a 34% (p = 0.038) increase in the autophagic activity (Figure 16 A) and 18% (p = 0.006) 
increase in the lysosomal activity (Figure 16 B) compared to nsiGDF-15 MΦ incubated 
in medium. It is of note, that starvation was induced in non-transfected THP-1 MΦ, which 
were starved for 4h in medium not supplemented with fetal-bovine-serum, followed by 
normalization against medium-incubated nsiGDF-15 MΦ   
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Figure 16: Autophagic and lysosomal activity in nsiGDF-15 and siGDF-15 THP-1 MΦ after exposure 
to oxLDL or after incubation in medium. (A) Autophagic activity (in % of nsiGDF-15 MΦ incubated in 
medium = 100%) in nsiGDF-15 / siGDF-15 THP-1 MΦ determined using fluorescent Cell Meter™ Autophagy 
Assay Kit [OD333/518]. Five independent experiments were performed. Data are presented as mean ± SEM. 
(B) Lysosomal activity (in % of nsiGDF-15 MΦ incubated in medium = 100%) in nsiGDF-15 / siGDF-15 THP-
1 MΦ determined using LysoBrite™ Red [OD575/597]. Four independent experiments were performed.  
Data are presented as mean ± SEM. *p < 0.05, ***p < 0.001 significance vs. nsiGDF-15 MΦ incubated in 
medium, +p < 0.05 significance vs. siGDF-15 MΦ incubated in medium. Student-Newman-Keuls test. 
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3.2 rGDF-15 enhances autophagosome formation and amplifies 
oxLDL-induced autophagic flux impairment 
3.2.1 THP-1 MΦ ingest rGDF-15 
In order to investigate the effect of extracellular GDF-15 on MΦ autophagy and lipid 
homeostasis, further experiments were performed using rGDF-15 produced in 
Escherichia Coli. After incubation of PMA-differentiated THP-1 MΦ with 1.0 µg/ml or  
1.5 µg/ml rGDF-15 for 4h, the cellular GDF-15 protein level was determined using a  
GDF-15 Elisa Kit. As control, THP-1 MΦ were incubated for 4h in medium alone.  
In medium-incubated THP-1 MΦ, the GDF-15 protein level was 35.7 pg/µg protein. 
Incubation of THP-1 MΦ with 1.0 µg/ml or 1.5 µg/ml rGDF-15 increased the  
cellular GDF-15 protein level about 82% (p = 0.029) to 65.2 pg/µg protein and  
99% (p = 0.014) to 71.2 pg/µg protein compared to THP-1 MΦ incubated in medium 
(Figure 17). THP-1 MΦ exposed to 50 µg/ml oxLDL had 28.4 pg/µg cellular  
GDF-15 protein level after 4h, showing no significant changes compared to medium-
incubated THP-1 MΦ (Figure 17). Additionally, after co-incubation of THP-1 MΦ with  
1.0 µg/ml rGDF-15 / oxLDL and 1.5 µg/ml rGDF-15 / oxLDL cellular GDF-15 levels 
increased about 93% (p = 0.002) to 61.7 pg/µg protein  and 122% (p = 0.002) to  
72.2 pg/µg protein compared to oxLDL-exposed THP-1 MΦ (Figure 17).  
 
Figure 17: Intracellular GDF-15 protein level in THP-1 MΦ after exposure to rGDF-15 with / without 
oxLDL. ELISA [OD490/655] was used to determine intracellular GDF-15 levels (pg/µg protein). Eleven 
independent experiments were performed. Data are presented as mean ± SEM. *p < 0.05 significance vs. 
THP-1 MΦ incubated in medium, ##p < 0.01 significance vs. THP-1 MΦ + 50 µg/ml oxLDL. Student-Newman-
Keuls test and Dunn’s test. Data published in Ackermann et al., 2019b. 
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3.2.2 rGDF-15 enhances lipid accumulation in human THP-1 MΦ  
The oxLDL-induced foam cell formation and the rGDF-15-effect on lipid accumulation 
were determined by Oil-Red-O-staining (Figure 18). Light microscopy pictures were 
taken to control the successful lipid uptake (Figure 18 A-D). THP-1 MΦ incubated with 
rGDF-15 showed an increase of neutral lipid content of about 10% (1.0 µg/ml rGDF-15; 
p < 0.05) and of 17% (1.5 µg/ml rGDF-15; p < 0.05) compared to THP-1 MΦ incubated 
in medium alone (Figure 18 E). Exposure of THP-1 MΦ to oxLDL resulted in a 37%  
(p < 0.05) increased lipid accumulation compared to THP-1 MΦ incubated in medium. 
The co-incubation of THP-1 MΦ with rGDF-15 / oxLDL did not significantly influence the 
lipid accumulation compared to THP-1 MΦ treated with oxLDL alone, but enhanced the 
lipid content about 43% (1.0 µg/ml rGDF-15 / oxLDL, p < 0.05) and 42%  
(1.5 µg/ml rGDF-15 / oxLDL, p < 0.05) compared to THP-1 MΦ treated with rGDF-15 
alone (without oxLDL) (Figure 18 E).   
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Figure 18: Lipid content in THP-1 MΦ after exposure to rGDF-15 with / without oxLDL.  
(A-D) Representative photos of Oil-Red-O-stained THP-1 MΦ. Black arrows indicate lipid loaded cells. Scale 
bars 100µm. (E) Lipid accumulation (in % of THP-1 MΦ incubated in medium = 100%) measured by Oil-
Red-O-staining after isopropanol elution [OD510]. Data are presented as mean ± SEM. Six independent 
experiments were performed. *p < 0.05 significance vs. THP-1 MΦ incubated in medium,  
+p < 0.05 significance vs. THP-1 MΦ incubated without 50 µg/ml oxLDL. Student-Newman-Keuls test.  
Data published in Ackermann et al., 2019b. 
To evaluate, if the changes in the lipid accumulation are due to altered cholesterol levels, 
a cholesterol assay was performed, measuring the levels of total cholesterol (TC), free 
cholesterol (FC) and cholesteryl ester (CE) (Figure 19). After exposure of THP-1 MΦ to 
rGDF-15, oxLDL or in combination rGDF-15 / oxLDL, the levels of TC, FC or CE were 
similar as in THP-1 MΦ incubated in medium alone (Figure 19 A-C).  
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Figure 19: Cholesterol levels in THP-1 MΦ after exposure to rGDF-15 with / without oxLDL. (A) TC, 
total cholesterol, (B) FC, free cholesterol, (C) CE, cholesteryl ester in THP-1 MΦ after exposure to rGDF-15 
with / without oxLDL. Results are expressed in mg/dl. Four independent experiments were performed.  
Data are presented as mean ± SEM. Data published in Ackermann et al., 2019b. 
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3.2.3  rGDF-15 affects basic autophagy by increasing autophagosome 
formation and aggravates the oxLDL-induced autophagy impairment 
To confirm a GDF-15-silencing-dependent impairment of the autophagic process, we 
analyzed the protein levels of ATG5 and ATG12 / ATG5-complex using THP-1 MΦ 
exposed to rGDF-15 with and without oxLDL. Incubation of THP-1 MΦ with rGDF-15 or 
50 µg/ml oxLDL alone did not affect the protein level of ATG5 (Figure 20 A,C) and of the 
ATG12 / ATG5-complex compared to THP-1 MΦ incubated in medium (Figure 20 B,C) . 
The co-incubation of THP-1 MΦ with rGDF-15 / oxLDL increased the ATG5 protein level 
about 48% (1.0 µg/ml rGDF-15 / oxLDL; p = 0.029) and 47% (1.5 µg/ml rGDF-15 / oxLDL; 
p < 0.001) compared to THP-1 MΦ exposed to rGDF-15 alone (without oxLDL)  
(Figure 20 A,C). Furthermore, a 38% (p = 0.004) increase in the ATG5 protein level was 
induced by the co-incubation of THP-1 MΦ with 1.5 µg/ml rGDF-15 / oxLDL compared 
to THP-1 MΦ incubated with oxLDL alone (Figure 20 A, C). Additionally, co-incubation 
of THP-1 MΦ with rGDF-15 / oxLDL increased the ATG12 / ATG5-complex protein level 
about 107% (1.0 µg/ml rGDF-15 / oxLDL, p < 0.001) and 140% (1.5 µg/ml rGDF-15 / 
oxLDL, p < 0.001) compared to THP-1 MΦ exposed to rGDF-15 alone (without oxLDL) 
(Figure 20 B,C). Moreover, incubation of THP-1 MΦ with 1.0 µg/ml rGDF-15 / oxLDL 
increased the ATG12 / ATG5-complex protein level about 59% (p = 0.012) and  
1.5 µg/ml rGDF-15 / oxLDL about 85% (p = 0.007) compared to THP-1 MΦ incubated 
with oxLDL alone (Figure 20 B, C). 
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Figure 20: ATG5 protein and ATG12 / ATG5-complex protein levels in THP-1 MΦ after exposure to 
rGDF-15 with / without oxLDL. (A) ATG5 and (B) ATG12 / ATG5-complex protein levels (in % of THP-1 
MΦ incubated in medium = 100%) in THP-1 MΦ. Expression was normalized against α-tubulin and quantified 
with ImageJ. (C) Representative Western Blot images for ATG5, ATG12/ATG5-complex and α-tubulin. Six 
(ATG5) to four (ATG12 / ATG5-complex) independent experiments are presented as mean ± SEM. #p < 
0.05, ##p < 0.01 significance vs. THP-1 MΦ + 50 µg/ml oxLDL, +p<0.05, +++p < 0.01 significance vs. THP-1 
MΦ incubated without 50 µg/ml oxLDL. Student-Newman-Keuls test (ATG5) and  
Holm-Sidak test (ATG12 / ATG5-complex). Data published in Ackermann et al., 2019b. 
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The impact of rGDF-15 with and without oxLDL on the autophagic flux of THP-1 MΦ was 
once again verified by observing p62 status (Figure 21). Incubation of THP-1 MΦ with 
1.0 µg/ml rGDF-15 or 1.5 µg/ml rGDF-15 had no effect on the p62 protein level compared 
to medium-incubated THP-1 MΦ (Figure 21 A, B). Whereas exposing THP-1 MΦ to  
50 µg/ml oxLDL increased the p62 protein level about 31% (p = 0.065) compared to 
medium-incubated THP-1 MΦ. Co-incubation of THP-1 MΦ with  
1.5 µg/ml rGDF-15 / oxLDL increased the p62 protein level about 80% (p < 0.05) 
compared to THP-1 MΦ exposed to 1.5 µg/ml rGDF-15 alone. Additionally, THP-1 MΦ 
exposed to 1.5 µg/ml rGDF-15 / oxLDL showed a 66% (p < 0.05) enhanced p62 protein 
level in comparison to THP-1 MΦ incubated with 50 µg/ml oxLDL alone (Figure 21 A, B). 
Furthermore, after incubation of THP-1 MΦ with 1.5 µg/ml rGDF-15 p62 accumulation 
significantly (p < 0.05) increased about 26% compared to THP-1 MΦ incubated in 
medium (Figure 21 C). Incubation of THP-1 MΦ with 50 µg/ml oxLDL enhanced the  
p62 accumulation about 49% (p < 0.05) compared to medium-incubated THP-1 MΦ 
(Figure 21 C). The co-incubation of THP-1 MΦ with 1.5 µg/ml rGDF-15 / oxLDL elevated 
the p62 accumulation about 60% (p < 0.05) compared THP-1 MΦ exposed to  
1.5 µg/ml rGDF-15 alone and 37% (p < 0.05) in comparison to THP-1 MΦ exposed to 
oxLDL (Figure 21 C). Once again, as a positive control for autophagy activity induction, 
THP-1 MΦ were starved for 4h. Upon starvation THP-1 MΦ showed a significantly  
(p = 0.006) 112% enhanced p62 accumulation compared to THP-1 MΦ incubated in 
medium.  
Regarding the diameter of intracellularly accumulated p62, rGDF-15 and oxLDL 
increased the diameter in THP-1 MΦ (1.0 µg/ml rGDF-15: 0.15 µm, p = 0.048;  
1.5 µg/ml rGDF-15: 0.14 µm, p < 0.0001; oxLDL: 0.11 µm, p = 0.039) compared to 
medium-incubated THP-1 MΦ (Figure 21 D). Upon co-incubation of THP-1 MΦ with 1.0 
µg/ml rGDF-15 / oxLDL or 1.5 µg/ml rGDF-15 / oxLDL diameter of intracellularly 
accumulated p62 expanded about 0.28 µm (p < 0.001) and 0.14 µm (p < 0.001) 
compared to incubation with 50 µg/ml oxLDL alone (Figure 21 D).  
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Figure 21: p62 protein level and p62 accumulation in THP-1 MΦ after exposure to rGDF-15 with / 
without oxLDL. (A) Total p62 protein level (in % of THP-1 MΦ incubated in medium = 100%) in THP-1 MΦ. 
Expression was normalized against α-tubulin and quantified with ImageJ. Six independent experiments were 
performed (B) Representative Western Blot images for p62 and α-tubulin. (C) p62 accumulation  
(in % of THP-1 MΦ incubated in medium= 100%) was analyzed with Fiji ImageJ and normalized against 
DAPI. (D) Diameter of intracellularly accumulated p62 were measured in µm using Fiji ImageJ.  
Seven independent experiments were performed. Data are presented as mean ± SEM. (E-J) Representative 
immunofluorescence images of p62 accumulations (red) and DAPI (blue) double staining, visualized with 
laser scanning microscopy (Nikon Eclipse). (G) The negative control shows THP-1 MΦ DAPI stained without 
primary antibody against p62. Scale bars 50 µM. *p < 0.05, **p < 0.01 significance vs. THP-1 MΦ incubated 
in medium, #p < 0.05, ##p < 0.01, ###p < 0.001 significance vs. THP-1 MΦ + 50 µg/ml oxLDL, +p < 0.05 
significance vs. THP-1 MΦ incubated without 50 µg/ml oxLDL. Student-Newman-Keuls test (p62 total protein 
and p62 accumulation), Dunn’s test (p62 accumulation diameter. Data (A-C; E-J) published in 
Ackermann et al., 2019b. 
In order to investigate the autophagic process in more detail, the expression and 
accumulation of lysosomal-associated membrane protein-1 (Lamp-1), a marker for 
lysosomes, was determined to quantify fusion of autophagosomes with lysosomes 
(Biazik et al., 2015). 
The exposure of THP-1 MΦ to 1.0 µg/ml or 1.5 µg/ml rGDF-15 resulted in  
a -22% decrease (p≤0.04) in the Lamp-1 protein level compared to THP-1 MΦ incubated 
in medium (Figure 22 A). Incubation of THP-1 MΦ with oxLDL led to -23% (p = 0.003) 
reduced Lamp-1 protein level in comparison to medium-incubated THP-1 MΦ. 
Additionally, Lamp-1 protein level in THP-1 MΦ was reduced after co-incubation with 
rGDF-15 / oxLDL (1.0 µg/ml rGDF-15 / oxLDL: -23%; 1.5 µg/ml rGDF-15 / oxLDL: -25%; 
p = 0.001) compared to medium-incubated THP-1 MΦ (Figure 22 A). Exposure of  
THP-1 MΦ to 1.0 µg/ml and 1.5 µg/ml rGDF-15 increased the Lamp-1 accumulation 
about 79% (p = 0.037) and 70% (p = 0.029) compared to THP-1 MΦ incubated in medium 
(Figure 22 B). THP-1 MΦ incubated with 50 µg/ml oxLDL showed 91% (p = 0.026) 
enhanced Lamp-1 accumulation compared to medium-incubated THP-1 MΦ.  
Co-incubation of THP-1 MΦ with 1.5 µg/ml rGDF-15 / oxLDL raised the Lamp-1 
accumulation about 95% (p = 0.029) compared to 1.5 µg/ml rGDF-15 alone and about 
74% (p = 0.054) compared to 50 µg/ml oxLDL alone (Figure 22 B). Additionally, 
starvation served as positive control for enhanced Lamp-1 accumulation  
(Zhou et al., 2013) and showed a 141% (p = 0.003) increase of Lamp-1 accumulation 
compared to THP-1 MΦ incubated in medium. Together with the number, the size of the 
Lamp-1 accumulations was evaluated (Figure 22 C). THP-1 MΦ co-incubated with  
rGDF-15 / oxLDL increased the diameter of intracellularly accumulated Lamp-1 about 
0.15 µm (1.0 µg/ml rGDF-15, p < 0.001) , 0.25 µm (1.5 µg/ml rGDF-15, p < 0.001) and 
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0.16 µm (50 µg/ml oxLDL, p < 0.001) compared to medium-incubated THP-1 MΦ. 
Comparing exposure of THP-1 MΦ to 1.0 µg/ml rGDF-15 with 1.5 µg/ml rGDF-15, the 
diameter of Lamp-1 accumulation rose 0.13 µm (p < 0.001). Upon co-incubation of  
THP-1 MΦ with 1.0 µg/ml rGDF-15 / oxLDL the diameter of accumulated Lamp-1 
decreased about 0.08 µm (p=0.002) compared to exposure with 50 µg/ml oxLDL  
(Figure 22 C).  
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Figure 22: Lamp-1 protein level and Lamp-1 accumulation in THP-1 MΦ after exposure to rGDF-15 
with / without oxLDL. (A) Lamp-1 protein level (in % of THP-1 MΦ incubated in medium = 100%) in THP-
1 MΦ. Expression was measured using Alexafluor 488 conjugated antibody against Lamp-1 [OD488/518] and 
normalized against total cell count (DAPI) [OD405/455]. Six independent experiments were performed. (B) 
Lamp-1 accumulation (in % of THP-1 MΦ incubated in medium = 100%) was analyzed with Fiji ImageJ and 
normalized against DAPI. Six independent experiments were performed. (C) Diameters of intracellularly 
accumulated Lamp-1 were measured in µm using Fiji ImageJ. Seven independent experiments were 
performed. Data are presented as mean ± SEM. (D-I) Representative immunofluorescence images of Lamp-
1 accumulations (green) and Dapi (blue) double staining, visualized with laser scanning microscopy (Nikon 
Eclipse). (E) The negative control shows Dapi-stained THP-1 MΦ without primary antibody against Lamp-1. 
Scale bars 50 µM. *p < 0.05, **p < 0.01, ***p ≤ 0.001 significance vs. THP-1 MΦ incubated in medium,  
##p < 0.01 significance vs. THP-1 MΦ + 50 µg/ml oxLDL, +p < 0.05 significance vs. THP-1 MΦ incubated 
without 50 µg/ml oxLDL, iiip ≤ 0.001 significance vs. 1.0 µg/ml rGDF-15. Student-Newman-Keuls test  
(Lamp-1 total protein and Lamp-1 accumulation), Dunn’s test (Lamp-1 accumulation diameter). 
In order to analyze the effects on the autophagic flux caused by rGDF-15 and oxLDL, an 
autophagy activity assay (Figure 23 A) and a lysosome activity assay (Figure 23 B) were 
performed. THP-1 MΦ exposed to 1.0 µg/ml or 1.5 µg/ml rGDF-15 showed an enhanced 
autophagic activity by about 20% (p = 0.039) and 16% (p = 0.018) compared to medium-
incubated THP-1 MΦ (Figure 23 A). Whereas incubation of THP-1 MΦ with  
50 µg/ml oxLDL diminished the autophagic activity about -26% (p = 0.013) compared to 
THP-1 MΦ incubated in medium. Moreover, co-incubation of THP-1 MΦ with  
1.0 µg/ml / 50 µg/ml oxLDL or 1.5 µg/ml rGDF-15 / 50 µg/ml oxLDL reduced the 
autophagic activity about -15% and -23% (p < 0.001) compared to medium-incubated 
THP-1 MΦ (Figure 23 A). Upon starvation, used as a positive control for  
autophagy-induction, the autophagic activity in THP-1 MΦ was significantly (p = 0.024) 
increased by 16% compared to medium-incubated THP-1 MΦ (Figure 23 A). 
Together with the autophagic activity a lysosome activity assay was performed. The 
lysosomal activity in THP-1 MΦ was not influenced upon exposure to rGDF-15  
(Figure 23 B), whereas 50 µg/ml oxLDL diminished the activity about -9% (p = 0.039) in 
comparison to medium-treated THP-1 MΦ. After the co-incubation of THP-1 MΦ with  
1.0 µg/ml rGDF-15 / oxLDL or 1.5 µg/ml rGDF-15 / oxLDL a decreased lysosomal activity 
of about -10% (p < 0.001) and -13% (p = 0.002) was detectable compared to THP-1 MΦ 
exposed to rGDF-15 alone (without oxLDL) (Figure 23 B). THP-1 MΦ on starvation 
showed no changes in the lysosome activity compared to medium-incubated THP-1 MΦ. 
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Figure 23: Autophagic and lysosomal activity in THP-1 MΦ after exposure to rGDF-15 with / without 
oxLDL. (A) Autophagic activity (in % of THP-1 MΦ incubated in medium = 100%) in THP-1 MΦ determined 
using blue fluorescent Cell Meter™ Autophagy Assay [OD333/518]. Four independent experiments are 
presented as mean ± SEM. (B) Lysosomal activity (in % of THP-1 MΦ incubated in medium = 100%) in THP-
1 MΦ determined using LysoBrite™ Red [OD575/597]. Five independent experiments are presented as mean 
± SEM. *p < 0.05 significance vs. THP-1 MΦ incubated in medium, +p < 0.01, +++p < 0.001 significance vs. 
THP-1 MΦ incubated without 50 µg/ml oxLDL. Student-Newman-Keuls test. 
In order to investigate the impact of GDF-15 on the autophagy machinery further 
upstream of the phagophore expansion, mTOR, a marker for the autophagy initiation 
and Beclin-1, a marker for phagophore nucleation were examined.  
Incubation of THP-1 MΦ with 50 µg/ml oxLDL led to 29% (p < 0.05) higher  
p-mTOR/mTOR ratio compared to medium-treated THP-1 MΦ (Figure 24). Upon 
exposure of THP-1 MΦ to 1.5 µg/ml rGDF-15 a 33% increase in  
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the p-mTOR / mTOR ratio compared to medium-incubated THP-1 MΦ was not significant 
(Figure 24). Co-incubation of THP-1 MΦ with rGDF-15 / oxLDL reduced the  
p-mTOR / mTOR ratio about -33% (1.0 µg/ml rGDF-15 / oxLDL) and -54%  
(1.5 µg/ml rGDF-15 / oxLDL) compared to oxLDL exposure, nevertheless these changes 
in the mTOR phosphorylation were not significant (Figure 24). THP-1 MΦ incubated with 
80 µg/ml Rapamycin, i.e. a mTOR phosphorylation-inhibitor, showed a -60% (p < 0.05) 
reduction in the p-mTOR / mTOR ratio compared to THP-1 MΦ incubated in medium 
(Figure 24). 
 
 
Figure 24: p-mTOR / mTOR protein level in THP-1 MΦ after exposure to rGDF-15 with / without oxLDL. 
p-mTOR/mTOR protein level (in % of THP-1 MΦ incubated in medium = 100%) in THP-1 MΦ. Expression 
was normalized against α-tubulin and quantified with ImageJ. Representative Western Blot images for 
mTOR, p-mTOR and α-tubulin. Four independent experiments were performed. Data are presented as mean 
± SEM. *p < 0.05 significance vs. THP-1 MΦ incubated in medium. One Way Anova test. 
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After exposure of THP-1 MΦ to rGDF-15 or oxLDL no significant changes in the Beclin-
1 protein levels compared to medium-incubated THP-1 MΦ were observed. (Figure 25). 
 
Figure 25: Beclin-1 protein level in THP-1 MΦ after exposure to rGDF-15 with / without oxLDL. Beclin-
1 protein level (in % of THP-1 MΦ incubated in medium = 100%) %) in THP-1 MΦ. Expression was 
normalized against α-tubulin and quantified with ImageJ. Representative Western Blot images for Beclin-1 
and α-tubulin. Four independent experiments were performed. Data are presented as mean ± SEM.  
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4 Discussion 
4.1 GDF-15 in THP-1 MΦ  
In the present work, THP-1 MΦ were rendered into foam cells, using oxidized (ox)LDL 
to investigate GDF-15-dependent MΦ lipid homeostasis and autophagy. This cell line 
was derived from an one-year old boy with acute monocytic leukaemia (Tsuchiya, 
Yamabe, et al., 1980). It is published that upon PMA-treatment, the cells become 
adherent, develop a MΦ-like phenotype and express surface markers like CD11b and 
CD14, which are known to be expressed in maturating monocytes (Schwende, Fitzke, et 
al., 1996). THP-1 MΦ are frequently used to study MΦ in vitro, since their homogenous 
genetic background minimizes the degree of variability in the cell phenotype (reviewed 
in Qin, 2012). This is advantageous for studying the biological function of chemicals with 
a high variability, such as oxLDL (reviewed in Qin, 2012). Furthermore, since transfection 
experiments in human primary monocytes and MΦ are often problematic, the 
downregulation of a protein of interest, using small interfering RNA (siRNA) is highly 
efficient in THP-1 (reviewed in Qin, 2012).  
In this study, the transfection of MΦ with GDF-15 siRNA successfully downregulated the 
GDF-15-mRNA in medium-incubated siGDF-15 MΦ (-75%) and oxLDL-treated  
siGDF-15 MΦ (-104%) compared to identically incubated control (nsiGDF-15) MΦ. On 
the GDF-15 protein level, a reduction from over 50% was achieved for medium- or  
oxLDL-incubated siGDF-15 MΦ compared to nsiGDF-15 MΦ. Upon oxLDL-exposure an 
increased GDF-15 mRNA expression (37%) was detected, data which are in line with 
results from Schlittenhardt et al. (2004). However, the oxLDL-dependent increased  
GDF-15 expression was not yet detectable on the protein level after 4h oxLDL-exposure. 
This is discrepant to the data from Schlittenhardt et al. (2004), which also detected a rise 
in the GDF-15 protein level after exposure to 50 µg/ml oxLDL after 4h. This could be due 
to the different origin of the cell types used to generate MΦ. Schlittenhardt et. al 
differentiated peripheral blood mononuclear cells isolated from healthy donors 
(Schlittenhardt et al., 2004). Whereas here, the THP-1 monocytes originate from an 
acute monocytic leukemia patient (Tsuchiya et al., 1980). Therefore, it is possible that in 
THP-1 MΦ, 4h exposure is not sufficient to induce the oxLDL-caused changes in the 
GDF-15 expression on the protein level. Since the oxLDL-induced upregulation of  
GDF-15 on the RNA level could be detected after 4h, it is likely that THP-1 MΦ would 
show an upregulation in the translation with extended exposure time.  
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The exposure of THP-1 MΦ to 1.0 µg/ml or 1.5 µg/ml rGDF-15 increased the intracellular 
GDF-15 protein level about 82% and 99%. Also, the co-incubation of rGDF-15 / oxLDL 
raised the GDF-15 protein level in THP-1 MΦ in a concentration-dependent manner, 
whereas exposure to oxLDL alone did not significantly change the GDF-15 protein level 
compared to medium-incubated THP-1 MΦ. Therefore, these experimental settings were 
chosen to be appropriate to investigate a possible impact of GDF-15 on MΦ lipid 
homeostasis and autophagy.  
4.2 GDF-15 and oxLDL independently influence lipid content in THP1 
MΦ  
The dysregulated lipid metabolism in plaque MΦ is one of the crucial events leading to 
plaque progression and necrotic core formation (reviewed in Maiolino et al., 2013). 
Normally, MΦ are able to regulate intracellular lipid content by reverse cholesterol 
transport, returning excess cholesterol to the liver for recycling or clearance (reviewed in 
Remmerie & Scott, 2018). In plaque-MΦ this protective mechanism is disturbed, leading 
to excess lipid accumulation and foam cell formation(Jeong et al., 2017). Previously, the 
cytokine GDF-15 was described to have regulatory effects on MΦ reverse cholesterol 
transport (Wu et al., 2014). Thus, in the present study, we tested whether downregulated 
(siGDF-15) or enhanced (rGDF-15) GDF-15 protein levels influence lipid accumulation 
and cholesterol levels after incubation of THP-1 MΦ with or without oxLDL.  
4.2.1 GDF-15 raises lipid droplet-content in THP-1 MΦ  
In the present work, THP-1 MΦ treated with 1.0 µg/ml or 1.5 µg/ml rGDF-15 for 4h 
showed increased, whereas GDF-15-silencing lowered the intracellular lipid 
accumulation. Surprisingly, THP-1 MΦ cholesterol levels (TC, EC, FC) were not altered 
upon modified intracellular GDF-15 protein levels. These  results  seem to be 
contradictive to findings from Wu et al. (2014), who reported an increased lipid efflux in 
THP-1 MΦ upon exposure to rGDF-15. They incubated PMA-differentiated THP-1 MΦ 
with 50 µg/ml oxLDL for 48h to fully differentiate the cells. Thereafter, MΦ were exposed 
to rGDF-15 in concentrations of 0.5 ng/ml, 1.0 ng/ml, 1.5 ng/ml and 2.0 ng/ml for 0-48h, 
followed by incubation with radioactive-labelled cholesterol for 72h. After assessing 
cholesterol levels with liquid scintillation counting, elevated cholesterol efflux was 
observed at concentrations exceeding 1.0 ng/ml rGDF-15 (Wu et al., 2014).  
This increased cholesterol efflux was implemented by increased ABCA-1 mRNA and 
protein expression, induced by rGDF-15 in a time- and dose-dependent manner  
(Wu et al., 2014). Nevertheless, the experimental setting from Wu et. al (2014) differs 
from the one implemented in this study. 
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Here, THP-1 monocytes were differentiated into MΦ by using PMA alone, whereas  
Wu et al. (2014) used PMA and 50 µg/ml oxLDL for 48h. Also, THP-1 MΦ were 
separately and for very much longer times exposed to oxLDL and rGDF15, followed by 
incubation with cholesterol for 72h (Wu et al., 2014). These considerable differences in 
the experimental setup may explain the contrary findings from Wu et al. (2014), where 
GDF-15 enhances lipid efflux. Whereas in this study, enhanced GDF-15 levels resulted 
in increased lipid accumulations. Even though, the GDF-15-dependent changes in the 
intracellular lipid accumulation were not accompanied by altered cholesterol levels, 
differences in the lysosomal accumulation could be observed.  
In our study, enhanced GDF-15 levels resulted in augmented accumulations of Lamp-1 
positive vesicles as well as their and size. These findings are in line with the here 
observed enhanced lipid accumulations, since MΦ process lipids in their lysosomes to 
store them in intracellular lipid droplets (Chistiakov et al., 2016). Whereas in our study, 
the lysosomal activity showed no differences upon enhanced GDF-15 levels. However, 
the observed changes in the lysosome accumulation could also be due to an increased 
autophagy activity, which was observed upon rGDF-15-exposure and is discussed in 
chapter 4.3. Under these circumstances, measuring the ACAT-1 enzyme activity would 
be helpful to clearly distinguish the reason for the changes in the Lamp-1 accumulation. 
An increased ACAT-1 activity upon rGDF-15 exposure would indicate that the enhanced 
Lamp-1 accumulations are, at least in part, due to the monitored augmented lipid 
accumulation. Additionally, the enzyme activity of LAL would be of interest, because the 
LAL-activity contributes to the processing of incorporated lipids and regulates the  
ABCA-1 expression (Bowden et al., 2011). Wu et al. (2014) attributed the  
GDF-15-enhancing lipid efflux to the activation of the transcription factor Sp1, which is 
found in the promotor region of the abca1 gene (Chen et al., 2011). A Sp1-binding side 
is also present in the promotor region of the gdf-15 gene (Böttner et al., 1999), as well 
as the lipa gene, encoding LAL (Ries et al., 1998). This would also set our findings in 
line with the reports from Wu et. al (2014), hinting that GDF-15 is involved in the  
ABCA-1 as well as the LAL induction at different time points in the signaling cascade. 
This further hints to GDF-15 as a regulatory cytokine involved in MΦ lipid handling and 
explains the GDF-15-dependent changes in the lysosome accumulation and lipid 
accumulation.  
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4.2.2 Exposure (4h) of THP-1 MΦ to oxLDL elevates lipid content without 
altering cholesterol levels 
Histochemical and biochemical studies described the presence of oxLDL in foam cell-
rich areas of advanced atherosclerotic lesions in men and rabbit (Rosenfeld et al., 1991; 
Ylä-Herttuala et al., 1989). Since then, numerous investigations concerning the 
homeostasis and processing of lipids in MΦ were performed. In the present work, 
exposure of THP-1 MΦ to 50 µg/ml oxLDL raised the lipid content independent of the 
GDF-15 status, when compared to medium-incubated THP-1 MΦ. Also, incubation of 
THP-1 MΦ with a combination of rGDF-15 / oxLDL did not further enhance the lipid 
accumulation significantly compared to oxLDL alone. Similar results were shown, i.e. in 
THP-1 MΦ exposed to oxLDL in concentrations between 20 µg/ml and 100 µg/ml for  
24 hours, revealing a time- and dose-dependent increase in the lipid content via  
Oil-Red-O-staining (Liu et al., 2016; Zhou et al., 2016; Yang et al., 2017).  
Surprisingly, here THP-1 MΦ showed no changes in the cholesterol level (TC, CE or FC) 
after exposure to 50 µg/ml oxLDL for 4h compared to medium-incubated THP-1 MΦ. 
THP-1 MΦ showed increased cholesterol levels after at least 48 h exposure with 
concentrations of minimum 30 µg/ml oxLDL (Batt, et al., 2004; Ma et al., 2018).  
In our study, the incubation time for THP-1 MΦ with oxLDL was significantly shorter than 
in the aforementioned publications. This could explain the unaltered cholesterol levels 
after 4h oxLDL-exposure. These observations are in line with groups, describing that the 
processing of oxLDL in MΦ is known to be much slower than e.g. the processing of 
acLDL (Ouimet et al., 2011; Roma et al., 1990). This explains the in this study non-
detectable changes in the cholesterol levels of THP-1 MΦ upon 4h oxLDL-exposure, 
since oxLDL is still processed to be stored as CE. The reasons for the differences in the 
MΦ processing of acLDL and oxLDL were investigated by Yancey & Jerome (1998). 
They compared the loading of THP-1 MΦ with acLDL- or oxLDL-derived cholesterol  
(both 125 µg/ml, 1-7 days). After 7 days, they found 64% to 88% of the acLDL-cholesterol 
in cytoplasmic inclusions, meaning lipid droplets, whereas 60% to 90% of the  
oxLDL-derived cholesterol accumulated in lysosomes (Yancey & Jerome, 1998).  
The cholesterol esterification was 75% less in THP-1 MΦ enriched with oxLDL compared 
to THP-1 MΦ enriched with acLDL (Yancey & Jerome, 1998). This impaired lysosomal 
hydrolysis of oxLDL is due to a reduced lysosomal enzyme activity and is reported 
multiple times for murine and human MΦ (Emanuel et al., 2014; Hoppe et al., 1994; 
Jessup et al., 1992; Li et al., 1998; Lougheed et al., 1991; Roma et al., 1992). During 
lysosomal hydrolysis, oxLDL gets trapped in the lysosome and causes its expansion 
(Griffin et al., 2005; Lougheed et al., 1999; Yancey & Jerome, 2001).  
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In the present study, oxLDL-induced lysosomal changes were already detectable after 
4h. THP-1 MΦ showed an enhanced accumulation of Lamp-1-positive vesicles, an 
increase in the size of these Lamp-1-positive vesicles as well as a diminished  
Lamp-1 fluorescence intensity upon oxLDL-exposure. This agrees with reports, where 
THP-1 MΦ exposed to 100 µg/ml oxLDL for 3 or 6 days showed large, swollen lysosomes 
(Jerome et al., 2008). Likewise, the increased size of the lysosomal compartment 
(Emanuel et al., 2014; Griffin et al., 2005; Lougheed et al., 1999; Yancey & Jerome, 
2001) and an increase in the number of acidified vesicles (Lougheed et al., 1999) are 
already published. Furthermore, our observations of a diminished lysosome activity upon 
oxLDL-exposure are in accordance with findings of other groups, reporting impaired 
lysosomal enzyme activity after oxLDL-exposure (Emanuel et al., 2014; Hoppe et al., 
1994; Jessup et al., 1992; Li et al., 1998; Lougheed et al., 1991; Roma et al., 1992). 
Trapped within lysosomes, oxLDL inhibits the ability to maintain an acid pH, mandatory 
for optimal enzyme function (reviewed in Jerome, 2006). This observed lysosomal pH 
increase is not due to an oxLDL-induced lysosomal membrane permeability  
(Emanuel et al., 2014). This type of membrane destabilization would result in cell death 
induction (Li et al., 2016), but oxLDL-loaded THP-1 MΦ remained viable for an extended 
period of time (Batt et al., 2004; reviewed in Tabas, 2002). Supposedly, the observed 
lysosomal pH-change upon oxLDL-exposure was caused by an increase in the  
FC-proportion in the lysosomal membrane (reviewed in Jerome, 2006; reviewed in 
Tabas, 2002). Since cellular membranes are composed of different lipids and, depending 
on the membrane requirements, a certain lipid-ratio is necessary to maintain the proper 
membrane fluidity, the resulting altered membrane properties inhibit the acidification 
process (reviewed in Jerome, 2006; reviewed in Tabas, 2002). The lysosomal 
acidification-process is depending on specialized ATPases, pumping protons into the 
lysosomal lumen (Crider & Xie, 2003). An altered membrane composition may disturb 
the transmembrane subunit of the v-ATPase, ultimately resulting in impaired lysosomal 
enzyme activity (Crider & Xie, 2003). The oxLDL-induced lysosome impairment was not 
only seen in vitro, i.e. ApoE-/- mice on western-diet for 2 month displayed lysosomal 
dysfunction in aortic-MΦ (Emanuel et al., 2014). 
To further investigate, to which extend the applied 50 µg/ml oxLDL get trapped in MΦ 
lysosomes after 4h, the use of 1,1′-dioctadecyl-3,3,3′3′-tetra-methylindocyanide 
percholorate (DiI)-labeled oxLDL (DiI-oxLDL) (Xu et al., 2010), together with a lysosomal 
marker would be suitable to test for a possible trapping of oxLDL in lysosomes. Although 
the trapping of oxLDL within MΦ-lysosomes is sufficiently reported, the here observed 
increase in the lipid accumulation, verified by Oil-Red-O-staining, indicates the 
processing of lipids upon oxLDL-exposure for storage in cellular lipid droplets. Batt et al. 
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(2004) exposed THP-1 MΦ with oxLDL (30 µg/ml total cholesterol, 48h) and detected an 
increased level of CE together with a rising amount of intracellular triglycerides (TG). 
Therefore, measuring the intracellular TG levels together with the enzyme activity of LAL 
and ACAT-1 would be suitable experiments to complement the present data for further 
insights into MΦ oxLDL-processing. Furthermore, lysosomes are involved in MΦ 
lipophagy for lipid breakdown (Ouimet et al., 2011). The present results concerning the 
aforementioned oxLDL-caused changes on lysosomal activity and morphology could 
likewise, at least in part, result from the processing of excess lipids through autophagy. 
The implications of oxLDL on MΦ autophagy and the associated lysosomal changes are 
further discussed in the following chapter. 
4.3 GDF-15 influences basal autophagy, but aggravates oxLDL-
induced autophagic flux impairment in THP-1 MΦ  
Initially discovered and investigated in yeast, in the last decades autophagy gained a lot 
of attention in the context of human cellular homeostasis. Defective autophagy is 
associated in the field of neurodegenerative, liver, muscle and cardiac diseases as well 
as cancer (reviewed in Levine & Kroemer, 2008). Until today, different forms of 
autophagy were described called macroautophagy, microautophagy or chaperone-
mediated autophagy and multiple substrate-specific subforms, such as aggrephagy 
(aggregated proteins), xenophagy (invading pathogenes), mitophagy (mitochondria) or 
lipophagy (lipid droplets) (reviewed in Søreng et al., 2018). In the context of 
atherosclerosis, autophagic flux acts atheroprotective but gets impaired during 
atherosclerotic lesion progression (Liao et al., 2012; Razani et al., 2012; Zhou et al., 
2016). In atherosclerotic plaques, autophagy relevant proteins were found to be mainly 
localized in MΦ (Razani et al., 2012), which are able to process excessive lipids through 
autophagy, called lipophagy (Ouimet et al., 2011). However, after prolonged exposure, 
oxLDL impaired autophagy in THP-1 MΦ (Liu et al., 2016) and peritoneal murine MΦ 
(Sergin et al., 2016). Interestingly in this context, GDF-15 colocalizes with oxLDL in 
plaque MΦ (Schlittenhardt et al., 2004) and is associated with MΦ lipid-handling (Wu et 
al., 2014). For the first time, this work shows the pivotal role of GDF-15 in MΦ autophagic 
processes and links GDF-15 to MΦ autophagy and lipid handling. 
4.3.1 GDF-15 facilitates autophagosome formation  
In this study, GDF-15-silencing in MΦ (siGDF-15 MΦ) led to an impaired ATG5,  
ATG12 / ATG5-complex and p62 protein level, as well as fewer p62 accumulations 
compared to nsiGDF-15 MΦ. This indicates a decreased autophagosome formation and 
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diminished autophagic flux. THP-1 MΦ exposed to rGDF-15 in concentrations of  
1.0 µg/ml or 1.5 µg/ml showed no increment in the ATG5, ATG12 / ATG5-complex and 
p62 protein levels. However, rGDF-15 enhanced the p62 accumulations as well as the 
size of the detected p62-positive accumulations. Based on the present results for 
nsiGDF-15 MΦ, siGDF-15 MΦ and rGDF-15 MΦ, GDF-15 seems to enhance 
autophagosome maturation, followed by increased autophagic flux. This could be 
accomplished by stabilizing the ATG5 protein or facilitating ATG12 / ATG5-complex 
assembly.  
These assumptions were confirmed by an autophagy assay, measuring the autophagic 
flux with Monodansylcadaverine (MDC). This auto-fluorescent substance was described 
to identify autophagic vesicles (Munafó & Colombo, 2001; Niemann et al., 2000).  
MDC accumulates upon amino acid deprivation in lipid-rich membranous compartments, 
which overlap with LC3 and LysoTracker, leading to an intensified fluorescence signal in 
an acid environment (Munafó & Colombo, 2001; Niemann et al., 2000; Vázquez & 
Colombo, 2009). This makes MDC a useful marker for autophagosomes and 
autophagolysosomes. In this study, in siGDF-15 MΦ the autophagic activity decreased 
compared to nsiGDF-15 MΦ and increased in THP-1 MΦ upon exposure to rGDF-15.  
Additionally, the lysosome activity was measured by LysoBrite™ Red, another 
fluorescent substance that selectively accumulates in lysosomes, supposedly through 
the pH gradient, where the acid environment enhances the fluorescence. Here, the 
lysosome activity in THP-1 MΦ was not impaired upon GDF-15-silencing or rGDF-15-
exposure. The proper usage and functionality of the autophagy and lysosome assays 
were assessed with starvation controls, meaning the deprivation of amino acids.  
This kind of starvation is known to induce autophagy and lysosome activity (Zhou et al., 
2013). Here, this was confirmed by the significant enhancement of autophagy and 
lysosome activity in starved THP-1 MΦ. Hence, GDF-15-silencing or rGDF-15-exposure 
only affected autophagosome formation in THP-1 MΦ, which would affect the fusion with 
lysosomes, but not necessarily influence lysosome activity.  
Consensual with this thesis, the accumulation and size of Lamp-1-positive vesicle 
increased upon rGDF-15 exposure, even if the lysosomal activity remained unaltered. 
This could be due to increased autophagosome and lysosome fusion, which does not 
necessarily require an increased lysosome activity, when autophagic flux occurs at basal 
levels. The observed diminished fluorescence of the Lamp-1 signal, indicating a 
decrease in the Lamp-1 protein level upon rGDF-15 exposure, does not seem to be 
compatible with an unaffected lysosome activity and increased Lamp-1 accumulation. 
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Lamp-1 and LysoBrite™ Red are often used indicators for lysosome formation and 
activity in context of autophagic flux, but there are limitations to these detection systems. 
LysoBrite™ Red is described to accumulate exclusively in lysosomes due to their acid 
pH and via proton pumps (AAT Bioquest, Sunnyvale, CA, USA). Depletion of individual 
v-ATPase subunits disrupts lysosome acidification, but does not affect autophagosome-
lysosome fusion, showing that a low lysosomal pH is not a prerequisite for fusion with 
autophagosomes (Mauvezin et al., 2015). Furthermore, lysosome reformation occurs by 
recycling lysosomal components from autophagolysosomes. Therefore, Lamp-1-positive 
tubules protrude and bud off from autophagolysosomal membranes after substrate 
degradation, to form protolysosomes (Yu et al., 2010). These protolysosomes lack 
lysosomal acidity, but are positive for different lysosomal membrane markers, becoming 
acidic after a short period of maturing into complete lysosomes (Yu et al., 2010). Also, 
there is evidence that Lamp-1 and Lamp-2 labeled organelles might be not exclusively 
lysosomes. These membrane proteins were found to exist on a wide spectrum of 
endocytic organelles lacking lysosomal hydrolases (Cheng et al., 2018). Considering 
this, Lamp-1-detection and lysosome activity assay depending on the GDF-15 level, 
should be complemented by assessing lysosomal hydrolase activity, e.g. by measuring 
cathepsin B or D.  
The hypothesis that GDF-15 influences ATG5 protein-stability and autophagosome 
elongation, is further supported by the non-impact of rGDF-15 on mTOR and Beclin-1 
protein levels, which operate further upstream in autophagy-signaling. Phosphorylation 
of mTOR, a known mechanism to inhibit autophagy induction, as well as Beclin-1, 
necessary for autophagosome nucleation (reviewed in Ryter et al., 2013), were not 
affected by rGDF-15. Therefore, the detected GDF-15 influence on ATG5 and 
autophagosome elongation cannot be due to GDF-15 operating further upstream in 
autophagy signaling. 
Since the autophagosome formation requires intense membrane remodeling and 
consumption, there are several cellular compartments (e.g. ER, Golgi apparatus, plasma 
membrane) discussed as possible membrane-contributing source (Dupont et al., 2014). 
Recently, autophagic structures were identified growing from neutral lipid stores in 
hepatocytes (Dupont et al., 2014). The triglyceride lipase PNPLA5 was identified to be 
mandatory for autophagy initiation and autophagic membrane biogenesis. An increase 
in the cellular lipid droplet content of hepatocytes increased the autophagic capacity, 
where LC3, ATG16L1 and PNPLA5 were found to colocalize with lipid droplets, 
initializing the growth of autophagic structures from lipid droplets (Dupont et al., 2014). 
This lipid droplet-enhanced autophagic capacity was dependent on PNPLA5 and in the 
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absence of lipid droplet build-up, autophagy still occurred, but at lower levels (Dupont et 
al., 2014). Since GDF-15 was found to influence the lipid accumulation and 
autophagosome formation in THP-1 MΦ, investigations of a possible relation between 
PNPLA5 and GDF-15 would be of great interest.  
Another interesting link between MΦ lipid homeostasis and autophagy is the role of the 
transcription factor Sp1, which is involved in the reverse lipid efflux, as well as found in 
the gene encoding gdf-15. Furthermore, this transcription factor was also associated with 
autophagy in different cell types. In prostate cancer cells, autophagic flux decreased with 
Sp1-depletion (Ling, Liu, et al., 2017). Contrary to this, Sp1-deficiency induced 
autophagy in gastric cancer cells (Xu et al., 2018). This further links GDF-15 to 
autophagy and lipid homeostasis in MΦ and hints to a regulatory role of GDF-15 in the 
signalling pathway of both processes. 
It is well described, that autophagy gets activated under numerous stress conditions,  
e.g. nutrition deprivation, growth factor withdrawal, oxidative stress, DNA damage or 
intracellular pathogens (reviewed in Maiuri, et al., 2013 and Moreau et al., 2010). 
Additionally, autophagy at basal levels occurs continuously as a quality control 
mechanism to clear and recycle aggregated proteins or dysfunctional organelles 
(reviewed in Denton et al., 2014). Thereby, basal autophagy maintains cell homeostasis 
and acts cytoprotective, constituting an initial barrier against apoptosis by promoting cell 
survival (reviewed in Marino et al., 2014 and Moreau et al., 2010). The switch from anti-
apoptotic to pro-apoptotic signaling occurs by cleavage of essential ATG proteins, when 
cell stress-intensity increases (Yousefi et al., 2006; Rubinstein et al., 2011). In supporting 
autophagosome formation and increasing autophagic flux at basal levels, GDF-15 
seems to act cytoprotectively to maintain a pro-survival signaling.  
4.3.2 oxLDL inhibits THP-1 MΦ autophagy 
Here, we show that THP-1 MΦ displayed no changes in the protein level of ATG5 or 
ATG12 / ATG5-complex after exposure to 50 µg/ml oxLDL for 4h. GDF-15-silencing 
resulted in a lower ATG5 protein level after oxLDL-exposure, compared to nsiGDF-15 
MΦ exposed to oxLDL. Whereas, the ATG12 / ATG5-complex surprisingly showed no 
significant reduction in oxLDL-exposed siGDF-15 MΦ. Even though, the difference in the 
ATG12 / ATG5-complex level between siGDF-15 MΦ and nsiGDF-15 MΦ after  
oxLDL-exposure is visible but not significant, additional repetitions should verify this 
observation. However, exposure to oxLDL increased the p62 protein level as well as the 
p62 accumulations in siGDF-15 MΦ, nsiGDF-15 MΦ and non-transfected THP-1 MΦ 
compared to medium-incubated siGDF-15 MΦ, nsiGDF-15 MΦ and non-transfected 
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THP-1 MΦ. Besides, siGDF-15 MΦ exposed to oxLDL had less p62 accumulations than 
nsiGDF-15 MΦ, even though p62 protein level in siGDF-15 MΦ and nsiGDF-15 MΦ 
showed no differences. Although these observations indicate an impaired 
autophagosome formation in siGDF-15 MΦ upon oxLDL-exposure, GDF-15-silencing 
showed no significant changes compared to nsiGDF-15, when oxLDL was added. 
Overall, oxLDL impaired the autophagic and lysosomal activity, as already suggested by 
the increased p62 accumulation. The lacking difference between siGDF-15 MΦ and 
nsiGDF-15 MΦ, concerning autophagy and lysosome activity, could be explained with 
an excessive impairing effect of oxLDL on autophagic flux and lysosome activity.  
Still, the significant decrease in the p62 accumulation and ATG5 protein level comparing 
siGDF-15 MΦ with nsiGDF-15 MΦ indicate a decrease in the autophagosome formation 
upon GDF-15-deficiency. The in this study observed impairing effect of oxLDL on MΦ 
autophagy conforms with other groups, describing the inhibitory effect of higher 
concentrations of oxLDL on autophagic flux (Fan et al., 2015; Li et al., 2015; Liu et al., 
2016; Sergin et al., 2016; Yang et al., 2017; Zhou et al., 2016). Zhou et al. (2016) found 
that low concentrations of oxLDL (5 µg/ml, 24h) increased the conversion of LC3 I to  
LC3 II, as well as decreased the p62 protein level, indicating an induction of autophagy 
to lessen lipid burden. However, at higher concentrations (≥ 20 µg/ml, 24h) oxLDL 
blocked the LC3I / LC3II conversion and the p62 protein level increased, leading to an 
impaired autophagic flux (Li et al., 2015; Liu et al., 2016; Yang et al., 2017; Zhou et al., 
2016). Similar observations were described by Sergin et al. (2016), where murine MΦ 
exposed to 50 µg/ml oxLDL for 6h to 24h showed increased p62 accumulations.  
In the present study, oxLDL-exposed THP-1 MΦ also displayed enhanced 
accumulations of Lamp-1-positive vesicles, which also increased in their size, when 
oxLDL was added. This indicates an enhanced number of lysosomes. However, the 
performed lysosome activity assay, revealed an impaired lysosomal activity. The 
increased diameter of Lamp-1 accumulation, but loss of lysosomal activity, upon oxLDL 
was already described by Emanuel et al. (2014). The here observed diminished 
lysosomal activity, conforms with results from other groups, where exposure to oxLDL or 
cholesterol crystals damaged MΦ lysosome membrane-integrity, leading to disruption of 
lysosomal pH and proteolytic capacity (Li et al., 1998; Duewell et al., 2010; Emanuel et 
al., 2014; Nihira et al., 2014). Furthermore, murine MΦ showed no co-localization of p62 
and Lamp-2 after 24h incubation with oxLDL, which indicates an inhibition of 
autophagosome and lysosome fusion or disruption of lysosomal membrane integrity. 
Koga and collegues (2010) described a decreased fusion-efficiency between 
autophagosomes and lysosomes in murine hepatocytes after 16 weeks on high-fat-diet. 
This was due to changes in the lipid composition of lysosomal- and autophagic-vacuole 
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membranes. Interestingly, low-levels of cholesterol in vitro and high lipid concentrations 
in vivo had the same cholesterol-lowering effect on the membrane composition of 
lysosomal- and autophagic-vacuoles (Koga et al., 2010). These changes ultimately 
resulted in decreased clearance of autophagosomes (Koga et al., 2010). This shows, 
that the autophagic pathway is highly sensitive to changes in the cellular lipid 
metabolism. The inhibitory effect of oxLDL on autophagic flux, seems to be by the 
disruption of lysosomal activity, which leads to accumulation of p62 due to ineffective 
autophagosome clearance. Here, we were able to show oxLDL-dependent impairments 
in the autophagic flux and lysosomal activity of THP-1 MΦ. To verify, if exposure to  
50 µg/ml oxLDL for 4h disrupts autophagosome and lysosome fusion, investigating the 
co-localisation of p62 and Lamp-1 would be advantageous. If the co-localisation of  
p62 / Lamp-1 decreased upon oxLDL-exposure, the observed increase in the 
accumulation of Lamp-1-positive vesicle and impaired lysosomal activity would be due 
to the trapping of oxLDL in lysosomes, before it is processed for storage in lipid droplets.  
To test whether the disruption of the lysosomal activity is the major inhibitory effect of 
oxLDL on MΦ autophagy, we tested the phosphorylation-status of autophagy regulator 
mTOR and the expression of autophagy-relevant protein Beclin-1. Here, we found that 
THP-1 MΦ showed an increased ratio in the protein level of p-mTOR / mTOR upon 
oxLDL-exposure. This indicates an inhibition of autophagy induction by mTOR, regulated 
by oxLDL. The increased phosphorylation of mTOR upon prolonged (10-48 hours) 
oxLDL-exposure is already described for THP-1 MΦ, human monocytes and murine MΦ 
(Ma et al., 2018; Sohrabi, Lagache, et al., 2019; Wang, Li, et al., 2014). As positive 
control for a decrease in the p-mTOR / mTOR ration, we used rapamycin. This agent is 
a known inducer of autophagy, by inhibiting the kinase activity of mTOR  
(reviewed in Liu et al., 2019). Here, 80 µg/ml rapamycin significantly decreased the  
p-mTOR / mTOR ration. The oxLDL-derived inhibition of autophagy-induction would 
consequently downregulate Beclin-1 protein levels, since it operates downstream of 
mTOR-signaling in autophagosome nucleation (reviewed in Kang et al., 2011). In this 
study, the Beclin-1 protein level showed no changes upon oxLDL-exposure, even if 
phosphorylation of mTOR was induced.  Yang et al. (2017) showed slightly diminished 
Beclin-1 protein levels in THP-1 MΦ upon 24h oxLDL-exposure, using 60 µg/ml oxLDL. 
Whereas p62 and LC3 II, autophagy-relevant proteins operating downstream in 
autophagy signaling, were already affected with lower oxLDL concentrations  
(Yang et al., 2017). Our data are in line with this, showing that oxLDL impairs autophagy, 
measured by p62 accumulation and autophagy activity assay, even though Beclin-1 
expression remained unaltered.  
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4.3.3 rGDF-15 aggravates oxLDL-induced autophagy impairment 
In this study, the co-incubation of rGDF-15 / oxLDL enhanced the protein levels of ATG5, 
ATG12 / ATG5-complex and p62 compared to oxLDL-exposure alone. Furthermore, 
incubation with 1.5 µg/ml rGDF-15 / oxLDL increased the number and size of  
p62-positive vesicles, as well as the number and size of Lamp-1-positive vesicles, when 
compared to oxLDL-exposure alone. The Lamp-1 fluorescence intensity remained 
depressed after rGDF-15 / oxLDL exposure compared to medium-incubated THP-1 MΦ. 
This implies a reduction in Lamp-1 protein level, which was already seen after exposure 
of THP-1 MΦ to rGDF-15 or oxLDL alone. These results suggest an enhanced 
autophagosome formation upon rGDF-15 / oxLDL exposure, but also an autophagic flux 
impairment. The unaffected Beclin-1 protein level and mTOR phosphorylation status 
upon rGDF-15 / oxLDL-exposure indicate that GDF-15 influences autophagosome 
formation but not the upstream autophagy signaling. In general, autophagy plays a 
cytoprotective role and autophagic activity intensifies when stress levels, like oxidative 
stress, increase (Liao et al., 2012; Marino et al., 2014). OxLDL is known to induce 
defensive autophagy in MΦ to lessen lipid burden, but in higher concentrations and with 
prolonged exposure, autophagy is impaired (Fan et al., 2015; Liu et al., 2016;  
Yang et al., 2017; Zhou et al., 2016).  
Based on the aforementioned observations, co-incubation with rGDF-15 / oxLDL 
enhances the autophagosome formation in THP-1 MΦ, indicated by elevated ATG5 
protein and ATG12 / ATG5- complex levels. Nevertheless, the inhibitory effect of oxLDL 
on THP-1 MΦ autophagy prevails upon exposure to rGDF-15 / oxLDL. This was shown 
by the increased p62 and Lamp-1 accumulations, as well as the decreased autophagy 
and lysosome activity, indicative of an impaired autophagic flux. OxLDL is reported to 
affect lysosomal activity and to decrease fusion efficiency between autophagosomes and 
lysosomes (Sergin et al., 2016), which conforms with the results showing decreased 
Lamp-1 protein levels and lysosome activity.  
Taken together, GDF-15 enhances autophagosome formation and autophagy activity. 
However, in addition with oxLDL an enhanced GDF-15 protein level aggravates 
accumulation of autophagic vacuoles and autophagic flux impairment. Since it is known 
that impaired autophagy triggers cell apoptosis (Liao et al., 2012; Liu et al., 2016), 
additional experiments would be to investigate the cell apoptosis and necrosis upon 
rGDF-15 / oxLDL exposure, to verify the aforementioned conclusions concerning the 
effects of GDF-15 on MΦ autophagy.  
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4.4 Conclusions – Role of GDF-15 in MΦ autophagy 
This work is the first one to demonstrate the pivotal role of GDF-15 in MΦ autophagy, 
using the human cell line THP-1 as a model for investigating MΦ autophagy.  
By influencing the autophagy-relevant proteins ATG5 and the ATG12 / ATG5-complex, 
GDF-15 promotes autophagosome formation. Thereby, GDF-15 increases autophagic 
flux, as shown by enhanced p62 and Lamp-1 accumulation as well as an increased 
autophagy activity. This process is illustrated in Figure 26 A, demonstrating the 
involvement of GDF-15 in autophagic processes during basal autophagy in MΦ. 
Furthermore, GDF-15 was found to enhance lipid accumulation in MΦ. This effect could 
be related to its role in MΦ autophagy, being an effect of lipophagy induction. Further 
investigations, concerning this GDF-15-effect on lipid homeostasis need to be executed 
to complement our current understanding concerning the involvement of GDF-15 in MΦ 
autophagy and lipid homeostasis.  
However, based on its role in MΦ autophagy, GDF-15 seems to aggravate  
oxLDL-induced autophagy impairment during excess lipid stimuli. Figure 26 B illustrates 
the effect of oxLDL on MΦ autophagy. After receptor-mediated uptake, oxLDL is 
processed in lysosomes, leading to the storage of esterified cholesterol and triglycerides 
in lipid droplets. During excess lipid stimuli, MΦ are able to process lipids through 
lipophagy, breaking down lipid droplets for export. Nevertheless, excess lipid 
accumulation is also known to inhibit autophagic degradation, leading to  
the accumulation of autophagic vacuoles. In promoting the autophagosome formation, 
GDF-15 aggravates oxLDL-induced accumulation of autophagic vacuoles.  
In the last years, a lot of promising therapeutic approaches in the field of atherosclerosis 
were investigated, using autophagy induction to reverse or slow down atherosclerotic 
progression. Even if further investigations are required to fully unravel the role of  
GDF-15 in MΦ autophagy and lipid homeostasis, the current insights reveal a promising 
potential for new therapeutic strategies e.g. in atherosclerosis.  
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Figure 26: Basal autophagy and autophagy after excess oxLDL-uptake in THP-1 MΦ. Model of (A) basal 
autophagy and (B) autophagy (lipophagy) after excess oxLDL-uptake in THP-1 MΦ. (A) Under normal 
conditions, basal autophagy promotes cell survival by degrading misfolded, aggregated or defective proteins 
or organelles. GDF-15 supports autophagosome formation by influencing ATG5 stability or ATG5 / ATG12-
complex formation. p62 chaperones for degradation marked, ubiquitinated proteins or organelles to the 
building phagophore and is sequestered along with its cargo within the maturated autophagosome. After 
fusion of the autophagosome with a lysosome, p62 and its cargo are degraded within the newly formed 
autophagolysosome by lysosomal enzymes. Afterwards, the released components are available for the cell 
or get exported. (B) After receptor-mediated uptake, oxLDL is enzymatically hydrolyzed in lysosomes and 
the emerging free cholesterol is stored in its esterified form within lipid droplets. To prevent foam cell 
formation, due to excess oxLDL uptake, lipid droplet breakdown is mediated through autophagy, called 
lipophagy. Thereby, lipid droplets, in whole or in part, are sequestered with p62 into autophagosomes. After 
fusion with a lysosome, lipids are enzymatically hydrolyzed to export the emerging free cholesterol out of 
the cell. Excess oxLDL-uptake blocks the lipophagy by blocking fusion of autophagolysosome, leading to 
accumulation of autophagosomes. Due to its enhancing effect on autophagosome formation, GDF-15 
aggravates oxLDL-induced accumulation of autophagic vesicles (Ackermann et al., 2019b; modified). 
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5 Summary / Zusammenfassung 
5.1 Summary 
Cardiovascular diseases are the leading cause of death, representing more than 30% of 
all global deaths. Risk factors for developing atherosclerotic alterations are hypertension, 
diabetes, obesity, nicotine or alcohol abuse, which are widespread among industrial 
nations. Atherosclerotic alterations concern human arteries, where infiltration of modified 
lipids triggers an immune response, initiating the transmigration of monocytic cells and 
smooth muscle cells to remove this subendothelial accumulated lipids. In this context, 
autophagic processes were found highly active in atherosclerotic plaques, especially in 
lesional macrophages (MΦ). Supporting the MΦ reverse cholesterol transport, 
autophagy aids to resolve the subendothelial lipid accumulation, promoting plaque 
reduction and plaque stability. Furthermore, the cytokine Growth-Differentiation-Factor-
15 (GDF-15) was found strongly expressed in lesional MΦ, where it is implicated in 
reverse cholesterol transport as well. These findings suggest a potential link between 
autophagy and GDF-15 in MΦ lipid homeostasis. This possible implication of GDF-15 in 
macrophages autophagy and lipid homeostasis was investigated in the present work.  
Therefore, we diminished or increased GDF-15 protein levels in human THP-1 MΦ, using 
small interfering RNAs and recombinant GDF-15 protein. Exposing THP-1 MΦ to oxLDL 
was used to induce foam cell formation. Subsequently, intracellular lipid accumulation 
and cholesterol levels, autophagy-relevant proteins, as well as autophagic and 
lysosomal activity were investigated.  
Aiming to investigate the basal autophagy in macrophages, we altered the GDF-15 
protein level without exposing THP-1 MΦ to oxLDL. Diminishing the GDF-15 protein level 
in THP-1 MΦ led to decreased intracellular lipid accumulations, whereas cholesterol 
levels remained unaltered. Furthermore, the ATG5 and p62 protein levels decreased, as 
well as the ATG12 / ATG5-complex levels. Additionally, the p62 accumulation and the 
autophagy activity were diminished. Since ATG5 and ATG12 are mandatory for the 
autophagosome formation and p62 accumulation represents autophagic vesicles, these 
observations indicated to a diminished autophagosome formation, which explained the 
observed reduction in the autophagy activity. An increased GDF-15 protein level did not 
influence ATG5 and p62 protein levels or the ATG12 / ATG5-complex. However, it 
enhanced the p62 and Lamp-1 accumulations and increased the autophagy activity, 
whereas the lysosome activity remained unaltered. Thus, we concluded that GDF-15 
possibly stabilizes the ATG5 protein level or facilitates the ATG12 / ATG5-complex 
assembly, leading to enhanced build-up in autophagic vesicles and thereby increasing 
the autophagy activity. To test, whether GDF-15 may operate further upstream in the 
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autophagy signaling pathway, we investigated the Beclin-1 protein level and 
phosphorylation status of mTOR. Amplified GDF-15 protein levels did not influence 
Beclin-1 or phosphorylation status of mTOR, which confirmed our conclusion about the 
impact of GDF-15 on MΦ autophagy being linked to ATG5 protein and/or ATG12 / ATG5-
complex.  
In exposing THP-1 MΦ to oxLDL, we induced foam cell formation. Upon oxLDL-
exposure, THP-1 MΦ showed increased lipid accumulation, whereas the cholesterol 
levels remained unaltered. The p62 and Lamp-1 accumulation were increased, whereas 
the autophagic and lysosomal activities were diminished. These results were in line with 
already published data, where oxLDL was reported to induce lipid accumulation and to 
lead to lysosome expansion and to disturb lysosomal activity. Likewise, our observations 
of impaired autophagy activity and accumulation of autophagic vesicles have already 
been described. 
In proceeding to investigate GDF-15-depending autophagy in foam cells, we exposed 
THP-1 MΦ with altered GDF-15 protein levels to oxLDL. The combination of an 
enhanced GDF-15 protein level in THP-1 MΦ and exposure to oxLDL increased the 
ATG5 and p62 protein levels and the ATG12 / ATG5-complex. Furthermore, increased 
GDF-15 protein levels in foam cells amplified the p62 and Lamp-1 accumulation, 
compared to oxLDL-exposure alone. Whereas an enhanced or diminished GDF-15 
protein level in combination with oxLDL-exposure had no additional influence on the 
autophagy and lysosome activity, which remained repressed just like after exposure to 
oxLDL alone. Conclusively, we found that increased GDF-15 protein levels aggravated 
the oxLDL-induced accumulation of autophagic vesicles, whereas vice versa decreased 
GDF-15 protein levels diminished the oxLDl-induced accumulation of autophagic 
vesicles. 
This work is the first one to reveal the crucial role of GDF-15 on MΦ autophagy: GDF-15 
acts protective during basal autophagy, whereas during excess lipid stimuli, this GDF-15 
influence on autophagosome formation aggravates the lipid-induced accumulation of 
autophagic vesicles. These observations identify GDF-15 as an important regulator in 
macrophage autophagy and lipid homeostasis, revealing its potential for new therapeutic 
strategies e.g. in atherosclerosis and cardiovascular diseases or stroke. 
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5.2 Zusammenfassung 
Herz-Kreislauf-Erkrankungen sind die häufigste Todesursache mit mehr als 30% aller 
Todesfälle weltweit. Risikofaktoren für die Entwicklung arteriosklerotischer 
Veränderungen sind Bluthochdruck, Diabetes, Fettleibigkeit, Nikotin- oder 
Alkoholmissbrauch, welche in den Industrie-Nationen weit verbreitet sind. 
Arteriosklerotische Veränderungen betreffen menschliche Arterien, bei denen die 
Infiltration modifizierter Lipide eine Immunantwort auslöst. Diese Immunantwort führt zur 
Transmigration monozytärer Zellen und glatter Muskelzellen, um diese subendothelialen 
Lipidansammlungen zu entfernen. In diesem Zusammenhang wurde eine erhöhte 
Autophagie-Aktivität in arteriosklerotischen Plaques, insbesondere in Plaque-
Makrophagen (MΦ) nachgewiesen. Diese erhöhte Autophagie-Aktivität trägt unter 
anderem zum Export von Cholesterin und somit zur Auflösung der subendothelialen 
Lipidansammlungen bei. Dadurch fördert Autophagie die Plaque-Reduktion und die 
Plaque-Stabilität. Darüber hinaus ist das Zytokin Wachstums-Differenzierungs- 
Faktor-15 (GDF-15) in Plaque- MΦ stark exprimiert, wo es am Export von Cholesterin 
beteiligt ist. Diese Beobachtungen deuten auf eine mögliche Verbindung zwischen 
Autophagie und GDF-15 in der Lipidhomöostase der MΦ hin, welche in der vorliegenden 
Arbeit untersucht wurde. 
Dazu wurde das GDF-15-Proteinlevel in humanen THP-1-Makrophagen vermindert oder 
erhöht. Erreicht wurde dies durch die Verwendung von small interfering RNAs oder 
rekombinantem GDF-15-Protein. Die Bildung von Schaumzellen wurde dabei durch 
Stimulation der THP-1-MΦ mit oxLDL induzieren. Anschließend wurden die intrazelluläre 
Lipidakkumulation und der Cholesterinspiegel, Autophagie-relevante Proteine sowie die 
Autophagie- und Lysosomen-Aktivität untersucht.  
Zur Untersuchung der basalen Autophagie in MΦ wurde das GDF-15-Proteinlevel 
modifiziert, ohne zunächst die Schaumzellbildung durch oxLDL zu induzieren. Die 
Verminderung des GDF-15-Proteinlevels führte zu einer verminderten intrazellulären 
Lipidanreicherung, während der Cholesterinspiegel unverändert blieb. Darüber hinaus 
erniedrigte sich das ATG5-Proteinlevel, das ATG12 / ATG5-Komplex-Level, sowie das 
p62-Proteinlevel, die p62-Akkumulationen und eine Verminderung in der  
Autophagie-Aktivität waren messbar. Da ATG5 und ATG12 essentiell für die 
Autophagosomenbildung sind und p62-Akkumulationen die Bildung von  
Autophagie-Vesikeln widerspiegeln, deuteten diese Beobachtungen auf eine 
verminderte Autophagosomenbildung hin, was wiederum die gemessene Verminderung 
in der Autophagie-Aktivität erklärt. Eine Erhöhung des GDF-15-Proteinlevels in  
THP-1- MΦ hatte keinen Einfluss auf das ATG5- und p62-Proteinlevel, oder die Bildung 
des ATG12 / ATG5-Komplex. Allerdings verstärkte es die p62- und  
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Lamp-1-Akkumulationen und erhöhte die Autophagie-Aktivität, während die  
Lysosomen-Aktivität unverändert blieb. Dies führte zu der Schlussfolgerung, dass GDF-
15 möglicherweise das ATG5-Proteinlevel stabilisiert oder die Bildung des  
ATG12 / ATG5-Komplex erleichtert, was die verstärkte Bildung und Anreicherung von 
Autophagie-Vesikeln, sowie die erhöhte Autophagie-Aktivität erklären würde. Ein 
erhöhtes GDF-15-Proteinlevel zeigte keine Auswirkungen auf das Beclin-1 Proteinlevel 
oder den Phosphorylierungsstatus von mTOR. Somit festigte sich die Schlussfolgerung 
bezüglich des Einflusses von GDF-15 auf die Stabilisierung von ATG5 und/oder die 
Komplexbildung von ATG12 / ATG5.  
Durch die oxLDL-Stimulation wurde die Schaumzellbildung in THP-1 MΦ induziert. Nach 
oxLDL-Stimulation zeigten THP-1 MΦ eine erhöhte Lipidakkumulation, während die 
Cholesterinwerte unverändert blieben. Die p62- und Lamp-1-Akkumulation nahm zu, 
während die Autophagie- und Lysosomen-Aktivität abnahm. Diese Ergebnisse standen 
im Einklang mit bereits publizierten Daten, in denen oxLDL eine Lipidakkumulation 
induzierte und zu einer Ausdehnung der Lysosomen führte, sowie die lysosomale 
Aktivität störte. Ebenso ist die hier nachgewiesene, gestörte Autophagie-Aktivität und die 
Akkumulation von Autophagie-Vesikeln bereits publiziert.  
Zur Untersuchung der GDF-15-abhängigen Autophagie in Schaumzellen, wurden  
THP-1-MΦ mit modifiziertem GDF-15-Proteinlevel ebenfalls oxLDL-exponiert. Die 
Kombination eines erhöhten GDF-15 Proteinlevels führte in oxLDL-exponierten  
THP-1 MΦ zu einer Erhöhung des ATG5- und p62-Proteinlevels, sowie einer vermehrten 
ATG12 / ATG5-Komplex-Bildung. Darüber hinaus führte ein erhöhtes  
GDF-15 Proteinlevel in Kombination mit oxLDL zu vermehrten p62- und  
Lamp-1-Akkumulationen, verglichen mit alleiniger oxLDL-Stimulation. Eine Erhöhung 
oder Verminderung des GDF-15 Proteinlevels hatte keinen weiteren Einfluss auf die 
Autophagie- und die Lysosomen-Aktivität, welche beide weiterhin vermindert blieben, 
wie bereits nach alleiniger oxLDL-Stimulation feststellbar. Zusammenfassend konnten 
wir nachweisen, dass ein erhöhtes GDF-15 Proteinlevel die oxLDL-induzierte 
Akkumulation von Autophagie-Vesikeln verschlimmert, während umgekehrt ein 
erniedrigtes GDF-15 Proteinlevel die oxLDL-verursachte Akkumulation von  
Autophagie-Vesikeln erniedrigt. 
Somit wurde in der vorliegenden Arbeit erstmals die entscheidende regulatorische Rolle 
von GDF-15 in der MΦ-Autophagie nachgewiesen. Durch Beeinflussung der 
Autophagosomen-Bildung wirkt GDF-15 während der basalen Autophagie schützend. 
Bei überschüssigem Lipid-Stimulus verschärft GDF-15 jedoch die lipidinduzierte 
Akkumulation von Autophagie-Vesikeln. Diese Erkenntnisse lassen sich möglicherweise 
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für neue therapeutische Strategien z.B. bei Arteriosklerose, kardiovaskulären 
Erkrankungen oder Schlaganfällen nutzen. 
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7 Appendix 
a. Data of two additional rGDF-15 concentrations on the ATG5, 
ATG12 / ATG5-complex and p62 protein level 
Besides the concentrations of 1.0 µg/ml and 1.5 µg/ml rGDF-15, we also tested  
rGDF-15 in the concentration of 20 ng/ml and 2.0 µg/ml. Therefore, 2 µg/ml rGDF-15 
was applied along with 1.0 or 1.5 µg/ml in the experimental setting depicted in  
Figure 4 B. Since 20 ng/ml rGDF-15 was tested along with transfected THP-1 MΦ (Figure 
4 A), we exposed nsiGDF-15 MΦ to 20 ng/ml rGDF-15 with or without 50 µg/ml oxLDL 
for 4h and normalized against nsiGDF-15 MΦ exposed to medium alone. On the  
ATG5 protein level, rGDF-15 in the concentrations of 20 ng/ml or 2.0 µg/ml had no 
significant influence (Figure 27 A, D). On the ATG12 / ATG5-complex level, exposure to  
2.0 µg/ml rGDF-15 / oxLDL significantly enhanced the complex build-up, compared to 
2.0 µg/ml rGDF-15 alone (Figure 27 B). Though, 2.0 µg/ml rGDF-15 did not further 
amplify the ATG12 / ATG5-complex build-up upon oxLDL-exposure, compared to  
1.5 µg/ml rGDF-15 co-incubated with oxLDL. 20 ng/ml rGDF-15 did not show any 
significant alterations in the ATG12 / ATG5 complex build up (Figure 27 E). 
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Figure 27: ATG5 protein and ATG12 / ATG5-complex protein levels in THP-1 MΦ, nsiGDF-15 MΦ and 
siGDF-15 MΦ after exposure to rGDF-15 with / without oxLDL. (A) ATG5 and (B) ATG12 / ATG5-complex 
protein levels (in % of THP-1 MΦ incubated in medium = 100%) in THP-1 MΦ. Expression was normalized 
against α-tubulin and quantified with ImageJ. (C) Representative Western Blot images for ATG5, ATG12 / 
ATG5-complex and α-tubulin. Six independent experiments are presented as mean ± SEM. #p < 0.05, ##p < 
0.01 significance vs. THP-1 MΦ + 50 µg/ml oxLDL, +p<0.05, +++p < 0.01 significance vs. THP-1 MΦ incubated 
without 50 µg/ml oxLDL. (D) ATG5 and (E) ATG12 / ATG5-complex protein levels (in % of nsiGDF-15 MΦ 
incubated in medium = 100%) in nsiGDF-15 / siGDF-15 THP-1 MΦ. ATG5 and ATG12 / ATG5-complex 
protein was normalized against α-tubulin and quantified with ImageJ. (F) Representative Western Blot 
images. Four independent experiments were performed. Data are presented as mean ± SEM. *p < 0.05,  
**p < 0.01 significance vs. nsiGDF-15 MΦ incubated in medium, #p < 0.05 significance vs. nsiGDF-15 MΦ + 
50 µg/ml oxLDL. Student-Newman-Keuls test (ATG5) and Holm-Sidak test (ATG12 / ATG5-complex). 
Data published in Ackermann et al., 2019a. 
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On the p62 protein level, 2.0 µg/ml rGDF-15 had no significant influence (Figure 28 A). 
The p62 protein level was enhanced in nsiGDF-15 MΦ exposed to  
20 ng/ml rGDF-15 / 50 µg/ml oxLDL, compared to nsiGDF-15 MΦ exposed to 20 ng/ml 
rGDF-15 alone (Figure 28 C). This observed significance is more likely caused by oxLDL, 
than by 20 ng/ml rGDF-15. Based on these observations, we decided to not further 
persue to investigate the influence of rGDF-15 in the concentations of 20 ng/ml and  
2.0 µg/ml. 
 
Figure 28: p62 protein level in THP-1 MΦ, nsiGDF-15 MΦ and siGDF-15 MΦ after exposure to rGDF-
15 with / without oxLDL. (A) Total p62 protein level (in % of THP-1 MΦ incubated in medium = 100%) in 
THP-1 MΦ. Expression was normalized against α-tubulin and quantified with ImageJ. Six independent 
experiments were performed (B) Representative Western Blot images for p62 and α-tubulin. Data are 
presented as mean ± SEM. ##p < 0.01 significance vs. THP-1 MΦ + 50 µg/ml oxLDL, +p < 0.05 significance 
vs. THP-1 MΦ incubated without 50 µg/ml oxLDL. Student-Newman-Keuls test (C) p62 protein level (in % 
of nsiGDF-15 MΦ incubated in medium = 100%) in nsiGDF-15 / siGDF-15 THP-1 MΦ. Expression was 
normalized against α-tubulin and quantified with ImageJ. Nine independent experiments were performed. 
(D) Representative Western Blot images for p62 and α-tubulin. Data are presented as mean ± SEM. 
*p < 0.05 significance vs. nsiGDF-15 MΦ incubated in medium, +p < 0.05, significance vs. siGDF-15 MΦ or 
nsiGDF-15 + 20 ng/ml rGDF-15 incubated without oxLDL. Student-Newman-Keuls test.  
Data published in Ackermann et al., 2019a. 
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